Hey everyone, welcome to the Drive podcast. I'm your host, Peter Aia. [music] Nav, good to see you again, my friend. >> Great to see you. Thanks for the invite. >> Well, thank you for coming down. I suspect that a number of people listening to us today may have not heard us speak eight, six, seven years ago. I don't remember. Uh and if they did, I'm sure it's easy to forget. And there's so much new stuff to talk about, but I always like to kind of ground people in um what the mitochondria are. Unfortunately, mitochondria has become one of the top 10 buzzwords on social media. So, um there's no chance that anybody listening or watching us um hasn't heard the term. Um but that second and third order understanding might be a little foggy. And given that we're going to talk so much about mitochondrial health, which is a big buzzword, uh mitochondrial boosters and all these other things, we do need to ground this discussion in what mitochondria are. So, take it away. >> Yeah, thanks again, Peter. I agree with you. I think it's not only mitochondria, but the other big buzzword is mitochondrial dysfunction. >> All right, that's the real buzzword which you hear over and over. So, if you're going to talk about mitochondrial dysfunction, you're absolutely right. Why don't we start with mitochondrial function? Now mitochondria do a lot of things things and I'm sure my colleagues will be like nav you didn't discuss X Y and Z so we're not going to discuss how mitochondria are made or degraded and and how many different kinds of mitochondria they may be there's a lot we can cover one thing mitochondrial function what do mitochondria functionally do most people know it as the powerhouse of the cell because it makes the ATP right and that gives you the power for your muscle your neurons to fire. And for a long time, um, most of us just thought about mitochondria as an ATP generator. So when mitochondrial dysfunction comes, let's say does it happen in aging or in heart failure, it's you don't have make enough ATP. Now remember glycolysis can also make ATP. So you have these, but mitochondria is much more efficient and can give you a lot more, right? So very simple and all the great theories around mitochondrial dysfunction related to any particular disease if it is causal or the natural aging process is all about ATP. Well, I'm here to tell you we're not going to talk about the ATP because there's a lot more they do. So just to back up, the electron transport chain is is generates a a protomotive force, basically a voltage which can be harnessed to make ATP. That process is coupled to something called the Kreb cycle or the TCA cycle. And it turns out that the TCA cycle is the anabolic engine also in your cells. So mitochondria do two things. They make ATP and they can make the building blocks, the metabolites that are the building blocks for new lipids, new nucleotides like DNA, RNA, right? Amino acids for for the building blocks of the protein. And that's kind of settled law. You know, people forgot that mitochondria is an anabolic engine. We we'll get into it with cancer in a second. And so that's what classically the great biochemist of the 20th century taught us. And that's like I said, it's in your textbooks. [gasps] What has changed in the last say 30 years and I think I've been part of that revolution. Um is that mitochondria also communicate, right? They're just not an organel sitting on the side. uh and you know things like mTor when they get activated or deactivated mTor is a big decision maker of metabolism your genes being turned on and off they're deciding cellul fate how a cell becomes a what it does right and mitochondria is just sitting there giving you ATP giving you metabolites it has no decisionmaking properties well that's changed >> can we back up for one sec now um and just give folks maybe a sense of size and scale so um are there any cells in the body that don't have mitochondria >> red blood cells. >> Okay. And um absent red blood cells when you consider all the other cells which have mitochondria what is the approximate cellular density of mitochondria? So depends. Yeah. So let's talk about a neuron. A neuron might have approximately how many? >> I actually I don't know these numbers to be honest with you. Uh the hpatocytes are full of them. Um but but again >> but we're talking thousands. Yeah. For sure. Maybe more. >> Maybe more. But again, and what instead of worrying about are they are they dense or they're not dense. I think if you look at them from what they're doing, there's the ATP, there's the metabolites. But what I really want to get into is the third aspect which a few mitochondria could probably fulfill. Well, and so that way you don't have to always think about mitochondrial biogenesis. I think that's what why you're asking this question. We're thinking of it in terms of supply and demand mismatch for example right so are they being paired to cells in density based on energy need or metabolite need because for example a hpatocy doesn't actually need much ATP but it needs a lot of anabolic precursor right so so >> it makes glucose for example >> so I assume that in the hpatocy the density is optimized more towards cat or anabolism Whereas in a very energy dense cell like a muscle cell where ATP is probably more important than precursor to building blocks, you're optimizing around this other function of ATP generation. That that's basically >> on on a first approximation that's true. Although because there's a third function that simple theory and and I don't disagree with that. I just don't think about it anymore in those simple terms because there's a third function that is becoming very dominant and I actually don't know this third function I'm going to talk about how it fits into that paradigm that you just explained right that and that's why I've stopped thinking about uh more or less mitochondria and that third function is that mitochondria are constantly generating signals to the rest of the cell and these signals are very are optimized for cellular function, right? So, what are these signals? So, one of them is the the electron transport chain is not a perfect system and it leaks electrons. It can leak a little bit of electrons or a lot of electrons to make H2O2 make super oxide first and then H2O2. People used to think H2O2 hydrogen peroxide in cells damaging damaging damaging. In fact, the oldest theory of aging says basically that as you get older, your mitochondria degenerate and they make copious amounts of H2O2 to cause degeneration of the muscle and the neuron. >> I I do want to just make sure people understand how that's happening and why it's happening. I think a little bit of biochemistry won't kill someone. So um when uh acetal COA is running through these four structures uh in the these four complexes across the electron transport chain >> well it's it's not that right acetal co is part of the KB cycle right so so right right so just yeah we can get into it yeah we can do a little biochemistry it's okay so you go from glucose to pyrovate pyate comes in the mitochondria uh pyate becomes a coa along with oxaloacetate to jumpst start the TCA a cycle. Let's just look at that first step. The pyate to acetal COA, it takes an NAD molecule and makes NADH. NADH is full of electrons. It goes to complex one and of the electron transport chain. Complex one takes that NADH2 electrons and makes NAD. The reason why people are so interested in NAD precursors is they're thinking their complex one is not working so well because it's not giving back the NAD to make mitochondria run to generate ATP in the TCA cycle. So if I give a lot of NAD maybe I can overcome the complex one deficit which is found in Parkinson's linked and whether it's linked to normal aging is debatable and we'll get into that. Right? And so that NADH electrons now are going to go down the electron transport chain with the final acceptor of those electrons being oxygen, right? So think of it as a um uh the best analogy I can think of is a waterfall, right? Through a tube and it's going through a tube into a tank and the tank is the the oxygen that's accepting all that water, right? There are holes, very tiny little holes in that in that tube. And that that's that leak. And that leak it can increase or decrease depending on how filled that tank is. Right? If the tank is completely full, all of that water backs up and now you get that leak happening because it it has to go somewhere, right? And uh and so that's a simple way to think about it that the best analogy I can think of is is you have this NADH which has these two electrons and it passes it down the electron transport chain to keep it simple. and oxygen is a final acceptor of it. Right? This allows the NADH when it passes those two electrons, it regenerates NAD and it keeps the TCA cycle going. Okay? But that electron transport chain isn't perfect. Not every electron always gets to oxygen. There's a little bit of imperfection, a little bit of leak and that one electron can take oxygen to something called super oxide which becomes quickly converted by some enzymes called superoxide dismutase to make H2O2. So what people thought is well the electron transport chain this slightly imperfect system becomes more imperfect. So now it's leaking more electrons in neuro degeneration and cancer and everything and now it's making copious amounts of H2O2. And is there evidence by the way Nav that even in an absent disease state as a person ages as they go from 10 to 20 to 30 to 40 to 50 to 60 what is what we represent in the textbook which is the final output after you've transferred all of the electrons and made all of the ATP you have two outputs carbon dioxide and water which is what we are all breathing out >> coupled to generating ATP. >> Yep. And is the idea that absent disease just aging increases the fraction of H2O2 relative to just H2O? >> I don't think so. >> Okay. Interesting. >> I think >> anyway I wanted to go through this just so people understand what H2O2 is relative to the normal process of H2O. >> Right. What you're asking me is uh in a normal person does the system become leaky >> just by age? >> Just by age? I don't think so. Uh, all right. I think this is one of the new paradigms. It's not written in stone yet, but this is what we've been working on. And not only that, but let's back off. To begin with, do we make copious amounts of H2O2 to levels that become toxic? I don't think so. >> Okay. And the way we >> Because we have a lot of antioxidants, Peter, that keep that in check. And if anything, >> explain to folks what an antioxidant is because [clears throat] we're taking it for granted as we say this. >> Yeah. Yeah. So it's just it's it's a protein that can detoxify different molecules of reactive oxygen species. So there's a there's an there's a family of proteins called superoxide dismutasis. They take super oxide and make H2O2. H2O2 when you make it has three choices. First choice which is it's it's almost happens is because we're full of proteins that degraded to water. So there's two classes. One is catalase is the other one is peroxy redoxins and we're full of they really have high reactivity to it and they convert it to H2O right so we have a system >> sorry I know I just I keep interrupting you but I just I don't want people to lose the the thread H2O is a very stable molecule okay so you have oxygen it has these covealent bonds to hydrogenable you have a couple electrons that can create polarity but why is Is it not reactive in a way that H2O2 is reactive >> because it can it's H actually H2O2 is not that reactive super oxide is super reactive if but there are cyines which can readily get oxidized is by H2O2 and that's part of the second thing that I was going to talk about which is this cyine on certain proteins and we don't quite know the code of that still well that that changes is the activity of that protein and That's all signaling thing that H2O2 with iron can undergo a fenton reaction to make hydroxal radical doesn't last long and is super toxic. It'll react with anything that it touches that can with a polyunsaturated fatty acid can make something called lipid peroxide and start a chain reaction which is now called ferroptosis. It's a new form of cell death discovered about 12 years ago. So the more we create H2O2, the more we theoretically risk this process, >> the ferroptosis process. That's exactly. So you make the H2O2 lots of proteins to get rid of it. You always need a little bit we think thing for that signaling that cysteine oxidation. But if you overwhelm these antioxidants for whatever reason and you know for some reason the antioxidant capacity goes down you start to push that not only for the signaling but you start to push it towards this feruptosis. >> And when people hear antioxidant they automatically I would assume think of things that we eat that are known to have antioxidant properties such as vitamin A or vitamin E or vitamin C. Yeah. So, how much of an individual's anti- oxidant buffer capacity is um a function of how much antioxidant they consume or is that an overly simplistic way to think of it? >> No. No. So, so the toxic ones that I'm talking about the lipid peroxide. So, vitamin E is pretty good at that at detoxifying that. Okay. U probably the biggest one is selenium. So the proteins that are responsible in our bodies to get rid of those lipid peroxides from so it's a battle right you're making these these hydrogen peroxide you're making lipid peroxides but we most of us have enough of uh for a lack of a better word antioxidant capacity Peter to keep those levels in check. So selenium right and there are there are countries by the way which are a little bit selenium deficient you know the northern New Zealand and Sweden Finland uh the US has a high selenium diet um and that's based on the soil >> the soil right so so so just to finish selenium um um is is is a is is required for the proper activity of of proteins like GPX4 which get rid of those lipid peroxides So you can imagine >> is that because it accepts electrons easily or >> the selenium is part of uh is part of the GPX4 commoy to make it work but but this is my point right it if you have a proper diet you should you should have enough antioxidant capacity there are places that may be deficient on it I just want to make one thing about vitamin C the granddaddy of them all as they say hey vitamin C and we're going to talk about going back to my signaling is a very important protein not for his antioxidants but as a co-actor for a whole class of enzymes called the alpha ketoglutarate dioxygenasis is the all the epigenetic clock stuff that people like this is run by these enzymes and vitamin C is needed to make sure those enzymes run two oranges a day is enough to make those enzymes run >> and so is it your point of view that all of the trials that have looked at supplementing with antioxidants they've all failed right they've no they've proven no health benefits >> some cases worse with cancer. Yes, we'll get into that. >> Is your hypothesis for why that's the case that A, we have sufficient enough antioxidants in the diet, so giving more doesn't really do anything. Is it B that um we're not taking enough? So the antioxidant trials failed because they failed to give enough and you would have to give really really really high doses to get the benefit or C that actually they do work but they're taking away the reactive oxygen species which we need to do something valuable or D something else. >> A and A and C in other words most of us have enough. I agree some countries may have low selenium so they may want to take selenium in them. Um there are people who don't eat enough oranges or have enough they're not scurvy but you know there's actually quite a large level of differences in vitamin C levels in people but generally if you're eating a healthy diet I think it's it's the A the other part is that people who are taking gobs of it might be interfering with the normal function. So remember I said something like H2O2 can become damaging if it becomes lipid peroxide. Something like vitamin E can take care of that. But there's also this need to keep the cyine oxidation this what I call signaling and that's my lab has really worked a lot on it and we've done genetic experiments where we decrease mitochondria's ability to make H2O2 for example well a TE-C cell when it sees a pathogen will proliferate okay but it won't make the memory T- cells >> so it actually hurts the T- cell >> it hurts the wells the immune cell hurts the immune system yeah for functioning properly and there are some data like in sepsis trials and in which have failed in fact made it worse there's the antioxidant trials in those cases so so I think we have enough and sometimes it might interfere with normal biology and I think this is a paradigm shift it used to be anti sorry bad bad take antioxidants it's a little nuanced H2O2 good within levels if it becomes lipid peroxides they can be managed due to these selenium dependent enzymes bingo that causes DNA damage and everything and >> all right so let's go from function to dysfunction >> can we just go back to function because I only talked about one of the is H2O2 sure uh there's a lot of them let me just give you two more just to which are important for this discussion and the second one is metabolites so those TCA cycle metabolites that are linked to electron transport chain including acetyl coa you just mentioned alpha keto alpha ketoglutarate so it turns out that protein acetellation when proteins get acetellated at lysines is a way to change their function and a lot of the acetal coa comes from mitochondria. So you could see how mitochondria controlling acetal coa levels >> which probably one of the three most important things that drives autophagy is acetilation of protein. >> Yeah. Well the big one is also in the histones being acetylated to keep a chromatin open or closed right >> that mitochondria control. So that's a signaling aspect of mitochondria. Now it has nothing to do with ATP, right? Alpha ketoglutarate. So there's 75 enzymes called the alpha ketoglutarate dioxygenasis. They use oxygen and alpha ketoglutarate. They use iron Fe2+ and they make suenate. It to recycle that iron you need vitamin C to make them functional. So when you don't have enough vitamin C, those enzymes aren't working. So let's just go through those. So now again you have alpha ketoglutarate as an input from mitochondria into running 75 I would argue some of the most important enzymes. So the enzymes that cause DNA methylation to be uh DNA demethylation or alpha ketoglutarate histone demethylasis the collagen prol hydroxilasis so you and I hopefully have good skin as we age are alpha ketoglutarate dioxygen. In fact, the vitamin C that people like to put on their skin, I always argue is because you keep the collagen prolyxilasis from working properly, right? And so, so now you have, you know, think about it, your DNA demethylation and right, if your DNA is hyperthylated, you typically turn off genes, right? it. So the epigenetic clock phenomenon and I think you've discussed a lot about whether it's of any value or you know and I'm not going to debate that right but all I'm going to say is that people who are so into their epigenetic clocks alpha ketoglutarate is controlling those clocks because they're needed to keep the demethylase reactions going properly. So now you have >> okay so that's our second major major function >> right so you have H2O2 [clears throat] you have TCA cycle metabolites controlling essentially epigenetics your third one is so mitochondria has its own DNA and RNA if it spills out the same sensors that look at pathogens so you know we have things that say I'm infected with a pathogen I have to turn on a cytoine well the mitochondria is your bacteria right it you know the current theory of how we have a normal you know a ukareot is an archa which is which is not a bacteria it's a kingdom by itself and alpha proteioacteria the two of them had a symbiosis as is before oxygen was around and and so there's a bacteria within us and if that bacteria releases it its DNA or its RNA it's it's viewed as a foreign and the same inflammation pathway >> sorry why is it that we didn't thyically be ex why were we not exposed to that in the early uh yeah basically why did our thymus not account for that because there must have been some disruption of mitochondria during embryogenesis. Great question. Actually, I don't know the answer to that. And but you know, uh, one thing could be that some of those antigens are not presented because, uh, they're not as easily presented because they're hidden and because they're in the mitochondrial matrix, right? It But the key point u um, just to sort of wrap this up, I mean, there's many other things that that that mitochondria release. Okay? And and again to the listeners especially my colleagues as just in the interest of time um uh we're going to for our discussions we're going to keep at least three of them. There's many more. One is H2O2 needed for immune function as we've needed for cell differentiation. Alpha ketoglutarate which we want to talk about later in the supplement section and keeping the epigenetics going in a proper way. And lastly, sometimes mitochondrial DNA or RNA being released is to turn on immune function. And again, like with immune function, if it's chronically, you know, some people think it's not your ATP. A Peter, you asked whether it's it's decreasing with age or H2O2 increasing. Could it be we just have leaky DNA from mitochondria? >> But why is that a good thing, Nav? Because >> No, no, no. I'm not saying chronically leaking is not a good thing. No, no, but I'm saying any you you mentioned earlier that if if the mitochondria releases its DNA and or RNA, it's going to activate the immune system because it's not identified as self. And but that activation of the immune system is very specific, right? >> So what is it targeting besides the the DNA and RNA of the mito? >> There's two big questions in that field. How it gets released, it's not known. It's not mphagy or >> people argue that improper mphagy might release it or the normal turnover fision fusion and where H2O2 we know how it's released. Alpha ketoglutarate has actual um transporters. This one is a bit of a black box but once it's released we know the targets c gas staining mavs for the RNA. So there's there's dedicated >> and what do those tea cells go and do? who do they turn their eye once they're activated >> right they can well not only te- cells but any any cell can release it and the the signals they release are type one interferons and which can then orchestrate the whole immune system but I think the question you're asking is is this a regulated system >> and is it for a net positive in other words is this something we are doing to amplify an immune response so if a virus comes in you if influenza comes along and attacks the edithelium or the epithelium rather of your throat is it also something that the immune that the mitochondria do say how can I participate and help the organism I'm going to release RNA and DNA it's going to make more interferon it's going to make more T- cells more B cells >> right right is that is that the the theory >> that absolutely in fact um uh people have done those sort of studies they've they've they've taken different viruses I did one and helped a colleague at Northwestern where they did pox viruses you know good old pox viruses is and lo and behold mitochondrial DNA A gets released is to turn on exactly what you're saying and >> what's the signal how does it know to do that? >> Yeah, exactly. So this is the so we so the mitochondrial DNA it so compare if I had to compare H2O2 versus the DNA H2O2 is still a black box what it hits which proteins which cyines to right we know how to manipulate mitochondrial DNA we know the receptors it's going to hit we just don't I don't think again people might argue I don't think we have a good explanation how it gets out and if we knew if there was a select transporter or something then we can manipulate and maybe even make drugs against it depending on what you want to do. But what I was going to get at is, you know, you have this mitochondria with two membranes. And I could imagine, Peter, a scenario where you're making enough H2O2, you're making enough ATP, you're making enough TCA cycle metabolites like alpha ketogluterate. So everything is great, right? But you know what's not great is maybe the membranes are not perfect and they're leaking a little bit of mitochondrial RNA or DNA. All right. And by releasing a little bit of mitochondrial RNA or DNA over 20, 30 years is causing a little bit of an immune response, a little low-grade inflammation all the time. You know, so some people think maybe the autoimmunity that you get as you age or the inflamming might be of leaky mitochondria. Not enough that it compromises DNA, not that it compromises alpha ketoglutarate or even my beloved H2O2 signaling, but it just sort of leaks out at low levels. And that's the the increase in inflammation that we're seeing. It's a hypothesis. It's difficult to test because we don't what exactly what you pointed out. How does it get out? Because if I knew how it got out, I could then come in and stop it in a mouse model or whatever and say, "Look, here's the aging." But inflamm aging and now it's not happening. Right. >> Yeah. Sorry, sorry to interrupt. Do you know NAV that it gets out of a cell that remains or does getting out imply that that particular mitochondria, that organel was destructed and it's binary? Anytime DNA and RNA get out, it means that particular organel is gone versus this idea of a leaky organel. >> Right? >> You hit it on the thing. This is >> we don't know that. We don't know. >> We don't know. Well, this is my problem with with with the the the idea. I have always assumed and that you know what we forgot to actually this is perfect segue. We I forgot to mention the most important experiment done in signaling by Ziao Dong Wong which got people like me inspired in the mid '90s to think of H2O2 and other things which was that he showed that cytochrome C which is part of the electron transport chain part of electrons flowing making ATP if it gets out from the mitochondria that cell goes on to die that is the death the mamalian death signal is cytochrome C getting released now there's something called where cytochrome C can get a little released and the mitochondria can repair itself. Many people think the mitochondrial DNA must be doing that. So in other words, it's not during cell death. When I first saw it is I was like the cell's about to die. It's just turning on inflammation. Exactly. On first principles, but it looks like there's improper maybe permeabilization or some leaky mechanism. I don't understand. And I'm I actually struggle with it. How does it really work? Right? Because to me it would seem binary but people argue now that cytochrome C even which is binary a that there is cytochrome C a little bit gets released and then it can repair itself of and it's turning on stress signaling. So more to be discovered on that front. So, let's put a bow on this because the two biggest and most obvious things that the mitochondria does, which is generate ATP, right? >> Anything that interrupt anything that interrupts that significantly is incompatible with organism life. >> That's not true. >> I mean cyanide, right? If you interrupt that process, we we done we're done, right? If you stop making ATP, you're dead, right? That's what I mean. So the cyanide one is an interesting one and uh because if you do these experiments genetically so cyanide binds to cytochrome oxidase is is um and and so does carbon monoxide and many other things. But if we genetically in a heart, okay, or in a dopaneric neuron and you would both you and I would both or even in a muscle, three bionergetically heavy things. Y >> there are signaling pathways such as activation of AMPK which can turn down mTor that cell lives fine >> for months and months and months as on glycolysis. So you're saying it's not that it evolves away around that particular complex within the mitochondria. That's very interesting. Why is >> And by the way, here's a here's a crazy thing. A colleague of mine at Northwestern and knocked out components of the electron transport chain. The heart continued to pump on glycolysis >> for how long? >> Months. And then but you know what happened? all this signaling that I'm talking about and he doesn't understand all of it but that signaling causes it to hypertrophy and now it can't contract and the mouse dies. >> But why is it that cyanide is so lethal in seconds? Why can't the organism survive on glycolysis for long a while? >> I think because when you when we genetically do it it and by the way I actually don't know why we which organ failed. So the ones that we've done right we don't actually know. uh same with rotinone which is a complex one inhibitor linked to Parkinson's right so if we do the same experiment in dopanergic neurons and those neurons basically live off glycolysis for three months in a mouse and then the neurons start to die but during those three months they stop making dopamine and >> right so in other words they have enough energy to live but not to be functional >> so I'll take I'll take my extreme statement back >> so so it's not about death >> it's just it's profound found dysfunction. So, so but >> but but but it's dysfunction and but the question is why is that dysfunctional? >> Yeah. So, but clearly top hierarchy function of mitochondria make ATP. Another big function of mitochondria is make metab metabolic building blocks. >> Right. And then the third one I'm calling 3A, 3B, 3C. And those are the three things you just talked about. >> Right. So that's the H2O2, that's the protein acidilation and hyone acidilation, all of the acetilation pathways. And then the third one which is I mean three call it 3C the really radical sounding one is actually it's to release genetic material to heighten immune response. >> Right. Right. Also the fourth one you could argue is cell death. Right. Cytochrome C release is when it gets released that cell typically goes on to die. And >> oh it's the whole cell not just that mitochondria. >> Oh no no no. Cytochrome C turns on caspaces >> within the it's the it's the it's the um apoptosis signal. >> Apoptosis signal. Yeah. the malian apo the dominant mamalian apotosis signal is when the cell gets neglected it for whatever reason and it releases cytochrome C and that cell goes on to die yeah so mitochondrial cell death um clearly is a is a big thing and there's many others as well you know your favorite mtor you know when mitochondria I think the reason in our experiments they can survive the organism or the organel I mean sorry the cell can survive high for long periods of time even though it's not functional because it's not making the signals or the metabolites is that EMPK gets activated when mitochondria don't make enough ATP and AMPK will tell mTor to to shut down the anabolic processes. So it's just saying let's hold on to the cell live off glycolysis. Yeah, we can't make all the building blocks or dopamine for a dopaneric neuron or you know but then there's some cells they still like the heart it still starts to grow. It's crazy. We don't quite understand all of this but this is a new way to think about I mean you know for the listeners I want them to not only think about ATP as the hierarchy not only the metabolites but all of these interesting communication of signaling. The nice thing about all these signals is if we know how how these signals are being released, maybe we can modify them in particular diseases. >> In a person listening to us or watching us who wants to know how well their mitochondria function, what what test can they do? I mean, I I have my favorite, but I want to know yours. >> I have none. >> You have none? >> I have none without taking a biopsy. >> All right. Well, tell me if you do a biopsy what you're going to do. What are you going to look at? You're where are you going to biopsy the muscle? >> Exactly. >> Okay. So, >> I don't know >> what what assay can you do in the lab? >> You can do metabolomics. That'll tell you your TCA cycle metabolites are up or down in a snapshot. It's not perfect. You can uh take those and do isolated mitochondria and you can look at maximal efficiency. I don't know how useful that is because here's the reason what human genetics has taught us from mitochondrial mutations. So you know the people [clears throat] who have genetic mutations either in their DNA, their nuclear DNA or their mitochondrial DNA which causes their proteins to be dysfunctional in their mitochondria. Uh and you have to lose 70% of mitochondrial protein function. >> It's that redundant. >> It is that much excess capacity. >> Well, that makes sense. I mean, if you're going to have something that is that critical to life, >> right? So you and I start, let's say, at 100%. Y >> and you can go all the way down to 70 and 80% in almost every tissue before >> 20 to 30 you mean? >> Yeah. Yeah. 20 to 30 sorry left remaining. So here's the analogy. You're a car guy remember. Right. Right. So we're going to use the good old Aston Martin because I like James Bond. Okay. The last one in No Time To Die I think the last movie that Astron Martin I looked it up uh yesterday. 217 miles an hour. My favorite one, the classic 1964 James Bond and the Goldfinger one goes about 140 miles an hour. Now, you could look at those two and say, "I don't want this one, man. This one's not This is in the city of Chicago. You can only drive 50. >> It's just not rate limiting. >> That's the best way to think of it. So, when you're measuring it, how do you figure out it's rate limiting?" >> Okay. Well, let me extend your car analogy then. This I love that analogy. You're looking at one parameter of the car, which is speed. is speed in your analogy ATP production. >> It is just the ability to maximally consume oxygen. >> Okay. So >> that's that's the first one by the way. >> Yeah. Yeah. So my question to build on your analogy is the newer Aston Martin doesn't only go faster, it's more fuel efficient. It has better suspension. It handles better. It has, you know, the transmission is infinitely better and smoother, etc., etc. So can you infer from function one? Remember I'm going to talk about these now as function 1 2 3 A 3 B 3 C etc. >> Can you infer from function one the capacity of two and three >> you can number two because what you can do in an isolated mitochondria uh is you can just feed it all sorts of carbons fatty acids pyrovate whatever you want and and ask how fast it can run at top speed. >> Yeah. But then you can also give it ADP and ask it how well it can make ATP. That's that fuel efficiency. So we can definitely do those two things things and and there are people and then also you can measure its ability to generate H2O2 >> but we have no idea what that tells us about its ability to control the immune system or these other much more nuanced properties. >> Right. And then there are parameters like you know their their metabolacted pyrovate ratio beta hydroxybutyrate acceto that's an NADH NAD surrogate that people use in my patients with mitochondrial mutations right it but you know if those levels are going to be really they have to be quite high in a normal person you're not going to I mean then there's something wrong right there's there's medically something wrong so you're talking about something as a a canary in the coal mine kind of >> so so here is my test here is my favorite way to determine mitochondrial function >> and it's purely focused on the on the first one. It is oxygen and ATP >> limited. You put a person on a bike or on a treadmill or something like that and you see how much work they can do in watts or METS while keeping lactate below 2 mill >> because as long as lactate is below 2 mill in steady state this person is maximizing mitochondrial capacity. Once lactate starts to rise you know that they have hit that threshold and now they are shunting through glycolysis. So the difference between me and Ted Pogachar, right, he's the greatest cyclist in the world. There's actually just an article that came out in a medical journal uh very recently that looked at the fact that his V2 max they predict is the highest of any professional cyclist ever. Um and his ability he can maintain 7 watts of output per kilogram longer than any cyclist they believe has ever been able to do so. So if you put me and Pagacha on a side to side erometer and we tested this, you know, once I hit about 230 watts, I'm going to start my lactate is going to start going up. I can't keep it below two. Pogachar is going to get to 350 watts. And if you normalize that for body weight, it's even more profound. He therefore has much healthier mitochondria than me. Would you agree? More efficient. Can I again I haven't thought about sports medicine as much as you have. So I'm gonna >> um ask you the question back. My understanding is that it's not only the mitochondria efficiency but the delivery of oxygen by the vascular that's the other determinant >> 100%. But at that point neither of us are rate limited by oxygen delivery. So how do you know that? I know that because um and we're only at about 60 to 70% of V2 max when we're at that state. >> So in other words, we're still well inside the envelope of of what the cardiac output is determining. So by the time cardiac output is limiting you, you are generally in a glycolytic state. >> Okay. So ju just to be also for the listeners and my for my own age, there is the the heart. >> Yes. >> There is the blood flow. So those are two inputs in the system. And the third one is how efficient mitochondria is using that oxygen to make ATP to keep you going so you don't use your phosphocreatine and glycolysis or lactate goes up. Those are the three inputs. And you're saying that you're measuring this at a time when you're at least confident that you're not you and this great cyclist >> and and anyone >> or anyone let's say is is not limited rate limited by by the contraction as well as the delivery and is simply the mitochondria. Yeah. >> Okay. Then I buy that. >> For most I mean we do this test on all of our patients. So for I've never seen a case where a person's what's called LT1 lactate threshold one which is about this zone two is not in the vicinity of 60 to 70% of V of ventilation max. >> Um >> now there are other components going on and I and I want to be thoughtful about it. This we're not going to go down the rabbit hole too much on this but of course you know the amount of type one muscle fiber a person has is going to play a role. There are other factors, but I guess my point, Nav, is [clears throat] this strikes me as a really good poor man's test for mitochondrial function. You can't have really healthy you can't do this without healthy mitochondria. And and you can't do what Pagacho does without very healthy mitochondria. >> But let's go back to my Bond analogy. As I age, do I need to have fuel efficiency, all of that? Even like the James Bond 1964 car? Probably not. It depends on how much physiologic reserve you want to have because at some point I mean using V2 max as an analogy. Okay. So um let's assume I measured your V2 max today and it was 42, right? That would I don't know I don't have a nomogram in front of me but I bet that would put you in the top quartile for your age. Yeah. >> Okay. >> That number is going down at about 10% per decade. >> Yeah. Yeah. Yeah. Now there is a point beneath which uh meaning there's a V2 max point that once you go below that >> it impacts daily living. >> Now that depends on [clears throat] what you define daily living as for Peter AIA that number is about 28 to 30. >> Once my V2 max falls below 28 to 30 milliliters per kilogram per day my quality of life will suffer dramatically. For some people that number is 20. But for virtually every human on this planet who wants to live independently, that number is about 15 or 16. So the argument I would have is everybody should have as high a V2 max as possible to give them as much optionality as posit as possible in the inevitable state of decline. And I think that is true for mitochondrial function. >> Two points going back to the the car analogy. You want to go at least you should be able to go 45 50 m an hour. If you have a car that's below that, that's not a functional car even in the city of Chicago. >> Well, not only that, you don't want to be at the red line going 45 to 50 miles hour to begin with because it's going to go down to 20. Violent agreement on that. Okay. My point is I am not convinced whether mitochondria okay to go 200 miles an hour yes as you need more efficient but whether mitochondrial function >> ah I agree with you. I I agree with you. I don't I don't know that. >> I don't know that. Right. So, so you made the analogy, you know, now if you can go 100 miles, but we want you to go 200 miles now. And guess what? We're going to boost your mitochondria to do that. Fair enough. And I'm like, you know what, Peter, I'm happy. I just need to maintain a 100 and because I'm going to have a a fall in it, but even that fall that happens, is that really because of mitochondria or is it because of neuromuscular? >> Totally agree. And that to me is the exciting question because I think on some areas um I think when it comes to maximum aerobic output I think the data look pretty clear that it's actually cardiac output that becomes limiting which means it is heart rate >> and stroke volume and contractility. Those are going to be your limit at max output. Right. when you when that um uh when that escalator is broken and you're late for your flight and you have to carry a suitcase that's 27 lbs and sprint up three escalators that is going to come down to cardiac output. Um but when it comes to more sustained aerobic efficient activity, yeah, I don't know how much of it is cardiac output versus mitochondria, etc. and and and and the and and the reason I think that the mitochondrial topic is so interesting is because of how frequently it is implicated in metabolic disease >> and that's why your work your life's work is a very interesting topic and we're going to talk about things like all of the potential targets including drugs like metformin but but anyway so I don't want to spend too much time on the theoretical but I want to set the stage for people why is this such a fascinating question I >> I I like this this this V2 discussion because we're working on exercise now to finally I think I probably have to thank you for that because uh you you you and just muscle health in general to ask this question. But what I would say is yes, could we find therapies to boost our mitochondria so we look like that cyclist so Peter can maybe take a supplement or something or a drug that that helps increase that efficiency. All and I just want your opinion on this. All I'm arguing is as we normally age, does the mitochondria become limiting for daily activities or even mild uh exercise to have a good quality of life? I'm not convinced of the latter. >> Yeah. And I think it's going to come down to >> because other things like >> what you said about stroke volume, oxygen delivery, you know, take your statins or you don't have aoscerosis, you got good, you know, good pipes giving you oxygen. And I think there's a component to this which is it depends on the individual. So there was a study that came out somewhat recently that looked at V2 max limitation in unfit and untrained individuals. >> And so it was a longitudinal study that followed unfit untrained non-ex exercising population. And in those individuals V2 max turned out to be more limited by peripheral oxygen transfer. And you might look at that and go oh my god that's really interesting. But then when you read the fine print, you realize that doesn't apply to anybody who's exercising or training. Once you start pushing the envelope a little bit, cardiac output becomes very limiting. And so I do wonder if on the mitochondrial function side, it also may have implications under well if you have a disease, if you have a if you have one of these many diseases that directly implicates mitochondria, the answer is this. If you are a very healthy, active person, the answer is this. And if you are a sedentary person, the answer is that. >> Completely. And you know you have to figure out all those things. >> Yeah. I mean we can both agree the three inputs in the system and you know the heart stroke volume and drill you know how how much is pumping the blood going to the right place and mitochondria extracting it. And it could be in three different population you have three different problems. >> Yeah. And and by the way I should be a little more accurate when I say cardiac output. I'm including hemoglobin in there. It's really oxygen delivery. So, so if you have a high cardiac output but a low hemoglobin, it's all it's all for not. >> But I think, you know, I I like what you just said here. We could have three different populations and what's limiting is the delivery but not the mitochondria or the mitochondria extraction but not the delivery. >> All right. So let's let's pivot and now talk a little bit about dysfunction and let's talk about it in the broadest sense we can which is do we believe that mitochondrial dysfunction is an inevitable consequence of aging given that it is designated as one of the OG hallmarks of aging. I am skeptical. Yeah. So a few times I'm going to bring up conflict of interest. I think it's important to say your conflict of interest. It is almost a conflict of interest for me to say that, right? If I want to make a living, I should tell people mitochondrial dysfunction is why you're aging and and lots of people do. >> I'm not so sure. Again, not in a diseased person. We can talk about the disease. We're talking about a normal healthy person. >> Let's talk about you and I. We're old men now, right? Relatively speaking, we're we're 10 years old. We're [laughter] 10 years old than when we first met. Okay. Yeah. >> No, I agree. The question is as uh going back to this analogy, a if you have to go to 70 80% of your efficient mitochondria for it to have a cell not work properly, do you ever get to that? The hallmarks are by the way, they're instructive, but they're misleading all the hallmarks. They are what's called a sufficiency experiment, right? It's what does that mean? That means if I take a mitochondria and I perturb it, so healthy mitochondria is this high and I make it here in a particular organ or an organism, it will degenerate and and maybe it'll age or look like aging. You could do it with the lysosome. You can make lots of cells scinsesscent and right. But that doesn't mean that normal aging that's what happens, right? In other words, does mitochond is mitochondrial dysfunction necessary for normal aging? it might be sufficient. So people have done what's a sufficiency experiment. All right? Which is they take mitochondrial DNA and they cause mutations in them genetically. So the mouse gets mutations only in their mitochondrial genome. People have done it with the nuclear genome and both of them age. I can tell you the nuclear the new nuclear genome mutations looks more like normal aging. mitochondrial ones that they've generated in normal aging will have this much mitochondrial mutations. Let's say you have to go almost 10fold higher mutations in order to start to see that organism degenerate in a mouse and it doesn't even look like a normal aging. >> So, let me make sure I understand that and replay it back to our listeners. Um, we're talking about something that we're taking for granted. I'll just state it quickly. Um, we have two genomes. We have a genome within the nucleus. That's the one we are almost always thinking about. But then the mitochondria have their own DNA and we should just make sure everyone understands that. Okay. >> If you take the DNA in this cell, what we're calling the nuclear genome >> and you apply mutations to it because as we age, we are acquiring mutations, >> you are you're saying you're able to replicate an aging phenotype by adding mutations to the nuclear. >> Not me. This is the work of others in the field. Let me be very clear. None of this. But but the field is >> yeah they've got some mouse the new mouse models where you have some nuclear uh DNA mutations at the same level as a normal aged mouse would and they have hallmarks of aging in that mouse somewhat. Now, conversely, when you take the mitochondrial DNA and not you again, but when the field takes mitochondrial DNA and they insert mutations >> and let the mouse age >> and let the mouse age, they do not see the same aging phenotype, even when they make those mutations at a rate of 10x what occurs normally. >> Right? So, normally you'll have this much mitochondrial mutations. If you make a mouse this early in life that has the same amount, nothing happens. Nothing happens. And then you get to this huge threshold, boom, you start to see this mouse degenerate. Some of it looks like aging, like hair loss for example, but some of it doesn't, you know, um, and some of the pathways that get activated. So, we took a cell recently called the micro ga, which is a very important cell for inflammation and and you know, for lots of things in the brain. And if you knock out mitochondrial function in that microg ga at one year it doesn't look like an aged mouse. >> Now Nav what if um what if the dysfunction of mitochondria does not come through genetic mutation? What if it comes through proteomic degradation? What if it comes through membrane permeability? What if it comes through anything that is downstream of transcription? What if it's a translational problem? >> Yep. So, just to back off, if we now I mean the reason we went through what mitochondria functionally do is you can now go back and and your three your three hierarchy thing. Do you lose ATP capacity as we age mitochondria? Probably not. Do we lose a TCA cycle? maybe not making enough metabolites, likely not. Do we lose some of this signaling? Right? So, in other words, instead of making too much H2O2, maybe we're not making enough >> in a certain immune cell or this leaky, you know, we went through this whole how is mitochondrial DNA might be leaky. You know, let's if it is leaky, you're not going to pick it up in the first two parameters of ATP TCA cycle. It's a different thing that's happening, right? So I would define if mitochondrial dysfunction is related to aging, it isn't simply about running out of ATP or running out of metabolites. It could be this miscommunication. >> Yeah. So it's not it's not the glib obvious first and secondord deficiency that probably gets us into trouble. It's one of these fourth order terms that is much more nuanced at a cellular level. >> Yeah. And we're trying to figure that out. We're trying to figure that out. So I can tell you oh at least when we take uh mice and we genetically don't let them make H2O2 enough their immune cells don't work for example they don't differentiate properly now does that happen as we age you know our ability to regenerate and all of that doesn't work as well is that because we're not making enough H2O2 for mitochondria or something else it's an open-ended question but I'm examining mitochondrial dysfunction not the lens of ATP not the lens of just making metabolites for growth that maybe not enough for example alpha ketoglutarate levels go down as we age so is that somehow causing problems uh for uh DNA methylation right which which could cause obviously age related defects >> so there are so many compounds I want to talk with you about um can we can we turn to metformin as the starting place >> okay so um you're one of the people who knows more about metformin than almost anybody. Um, you know, listeners of this podcast have heard me talk about metformin quite a bit. I've done many podcasts on it. I've had Near Bars on at least twice. I've also been on Andrew Huberman's podcast where I did a very very thorough journal club looking at both the Banister paper and the keys paper which were really the two massive epidemiologic studies. Uh the Banister paper was the one that really got people excited about metformin as a girotective agent. This is the study that looked at a cohort of the population and made an observation that non-diabetic people who took metformin had um wor pardon me non-diabetic people not taking metformin had worse outcomes than diabetic people taking metformin when it came to cancer. That basically got the idea going that metformin could be protective of cancer. >> Roughly 8 years later, a more in my opinion rigorous study came out that challenge those findings, ran the analysis two ways with and without a statistical tool used by the first analysis and it didn't find that at all. And and truthfully, I found the second study more convincing. That doesn't mean metformin doesn't work. It just means that the epidemiologic argument was more shaky. >> What about the phase three clinical trial in breast cancer that failed? >> Yeah. And then the prostate cancer trial. >> That one had some. >> So let's talk about them. Let's let's talk about them. So um give folks >> but I agree but I agree with what you just said by the way. >> Yeah. So so people have heard of metformin. I don't think there's anybody listening to us that hasn't. But I don't think a lot of people maybe understand the complexity of that drug and how many different things it does. So can you can you just explain to people how metformin works? >> Yeah. Well, again, to the best of our knowledge. Yeah. Yeah. >> Um, so let's just I think uh you and I have talked about this before. Let's just talk about any of the supplements we'll go through or any of the drugs. Most of them you take oral. Let's stick with that. The first pass is the gut, right? So with metformin and it goes in the gut and people have done this with C11 PET imaging. They can see the gut light up, right? The intestines, the colon light up. Then it goes through the portal vein to the liver. Then it goes there's the kidney and then it gets excreted out in a couple of hours. Right? It doesn't get in the brain. It doesn't get in the heart. It doesn't get in the muscle at appreciable levels. Why is that? Because metformin needs a transporter. The organic cation transporters. There's one, two, and three. There's some other ones as well, but let's just keep it simple. Well, the gut ends up taking it up quickly but releasing it in the portal vein slowly. So the highest concentration of metformin up to a millimmer wow is in the gut. By the time it gets to the liver it's less 50 microar 100 microar max. Right? it by the time it's in the blood at 10 microar. We have seen some immune cells macrofasages and T- cells certain types and other people have noticed that they will also take it up that you can't have the resolution uh when you do a a PET imaging analysis but but this part is really key and it's going to explain the cancer data in a second as well. You need the transporters. So the highest concentration is in the gut >> and everything after the gut um is so so when the gut absorbs the vascule of the gut. So the gut has the transporter obviously but does it otherwise diffuse into the portal circulation or does it also require the transporter in the portal circulation? >> It it requires it to take it up. It needs a transporter to dump it out of the entrites. So the metformin gets accumulated in the intestinal or the coline cells and but it takes a little bit longer less transporters to release it into the portal vein >> because that's a huge drop to go from 1 millm to 50 micro mole is a 20x drop. >> It's it's it's estimated as high as 1 millm but there is a huge drop in it. Now, here's here's the experiment that got me super excited about what why the gut. So, the original idea was metformin goes in the liver, it decreases hpatic glucose production. So, your liver, as you pointed out earlier, can make glucose. That's right. It's an is largely an anabolic uh um uh um organ. And so what people the oncologists have known this and you probably remember this that if you take metformin they and god forbid you have cancer they tell you to get off it because they use an FDG PET right a glucose tracer that they can easily see that lights up. Well if you take metformin and you give that glucose tracer guess where it lights up one place the gut. Okay. So why would it light up in the gut so much? A it's at a very high level. So every cell which has a mitochondria if I give it uh if I inhibit the electron transport chain the thing that's generating ATP and consuming oxygen to compensate for it it takes up glucose and goes through glycolysis to make the ATP deficit. So if you have a mitochondrial toxin the only way you survive is by sucking up as much glucose running it through glycolysis making lactate. >> Right. >> Right. anorobic uh fermentation, right? And uh so why would that happen? Well, about 25 years ago, biochemists noticed that mitochondria, sorry, uh um metformin can inhibit mitochondrial complex one. So this is a complex one that takes the NADH and makes NAD to keep the TCA cycle and does a lot of other signaling functions, right? So metformin and and this is interesting at least in that tissue might decrease mitochondrial NAD levels and increase mitochondrial NADH levels the opposite of what NR is doing or or the NAD supplements what people want NR >> people want NR to do right it and so um Colleen ResiC in my lab I want to give some shout outs here uh and Zach Zebo who's been doing the recent work on it uh so Colleen made a mouse where she took a yeast protein from yeast. So mamleian mitochondrial complex one is 50 45 subunits. Some are nuclear encoded genes products, some are mitochondrial. It's the largest complex. Look, it looks like a boot. Okay, it's huge. The yeast has a single protein which can work as a homodimer. The same protein comes together and it could do the same function as a mitochondrial complex one. In other words, take NADH to NAD, pass electrons to the rest of the transport. So there's some things it cannot do, but let's leave that aside. But basically, it's a bypass. So if you get rid of mitochondrial complex one, in many cases, this yeast protein can can overcome its loss. So we've done this in dopanergic neurons. We lose complex one and genetically we put this protein is called NDI1. Guess what? The neurons are fine again. So she made a whole mouse which expresses the mamalian complex one and the NDI1. And she just asked if I give metformin and what happens? Metformin typically lowers the glucose levels. If NDI1 is there, it's largely refractory. Arguing that complex one is the target. >> And do we think that the majority of this is happening in hpatocytes? Well, so so Zach, so she did a whole body. So Zach said, "Well, the largest place is going is in the gut. Let's start with the gut. Why the liver?" So he takes ND the same NDI1, he puts it only in the gut, nowhere else. And he does first he looks at that FDG PET scan and in a mouse. It's huge with metformin completely abrogated. So that implies that metformin must be inhibiting complex one. And that's why cuz NDI1 cannot be inhibited by complex one. So, so a normal mouse will have all this glucose uptake in the gut. But if you have the yeast complex one, which is refractory to metformin, bingo, it goes down. And so what he noticed is, and people have seen GDF-15 goes up with metformin. I don't know if you know that, right? So GDF-15 a right is a is a hormone. It tells you not to eat. It's an appetite suppressing. not at high levels. GLP-1 goes up all from the gut. There's one called lac field, lactate and fennel alanine. All of these abre aregated, right? We haven't done the colleen's doing the liver experiment to see how much the liver contributes. By the way, our paper, the second one I just talked about the intestine. It's a preprint that anyone can see. >> We'll link to it. Yeah. >> But I'll tell you uh something that Zach noticed uh which I think I give him a lot of credit for here. Uh he he was looking at metabolomics of people in metformin. Do you know what the number one metabolite goes down when people are on metformin? Citrine. Citrine. And the sports junkies know this. Citrine is taken up goes in the kidney becomes arginine and then the arginine uh uh can be used by the rest of the body for nitric oxide and keeping you vasoddilated. So the you can either absorb citrine or you can make citrilline. Citrine and you make from ornithane which requires mitochondrial ATP. So what he found is that in the intestant when mitochondrial complex was being inhibited those intestinal cells didn't make enough ATP and citrine levels dropped in the blood. The NDI1 the citrine levels didn't drop. Why am I making a big deal of citrine? Because there is a study out there which argues that, you know, you should take metformin while you eat, and we'll get into in a second, but long-term metformin use might compromise the exercise induced V2 max >> and hypertrophy >> and potentially hypertrophy. I would argue that maybe might be because of the citrilline. It doesn't get into the muscle, but I can imagine lowering your citrine. So, I just wonder. So you're saying if you're taking metformin it might or but but the without it it what it might be doing is inhibiting vasoddilation which inhibits the delivery of >> oxygen >> oxygen and or al altered other um nutrients that are necessary for metabolism. >> The other one is B12. So B12 levels go down with metformin. So people should take B12. And the reason people don't quite understand why but the idea is that the gut doesn't absorb it as well. But you know it's amazing Peter if you think about metformin when you and I started talking about it we talked a lot about the liver effects but the gut I mean whether it's it's the citruline effect whether it's the B12 effect oh I didn't even say people on metformin have a very positive microbiome the immunosophilia uh uh microbiome again I'm not a microbiome but it's always positive whatever the good microbiome is is metformin gives you that again a gut effect now how does that work I don't Oh, but my point is the gut seems to be a central player. Now, >> by the way, what happens when you give people intravenous metformin? Where does it get taken up? >> Liver, more so in the liver, >> not in the gut at all because the gut's not going to see it. >> It's not going to see as much of it. It gets more liver. And by the way, you know, the new metformin, the delayed release one, hangs out in the gut even longer to >> Does the muscle take it up in with introvenous? >> Uh, I don't know that. So that would suggest if assuming it does not it would suggest that any negative impacts of metformin on exercise performance probably are circulatory or metabol they're basically coming from some metabolite upstream >> right and I'm going to argue maybe B12 because if you have B12 deficiency you make something called methylalonic acid which can be a complex to inhibitor in the mitochondria I'm not saying that's the mechanism but I'm thinking exactly what you are that it's got to be something circulating most of it's in the gut some in the kidney and the liver or something from those organs is affecting I don't think this idea oh you have a complex one inhibitor now in the muscle and that's why your V2 and by the way the data on the V2 max and you should look at it yourself carefully it's not like it completely abolishes it and it's a short-term studies >> to me the the the really important question is are there girotective benefits to metformin so so let's examine the state of the science on it >> right so if you take metformin at the time you're having a meal and we've seen this in our experiments and it's the postprandial after eating a meal you have a glucose spike I'm sure people with glucose monitors can see that spike and depends on what kind of meal metformin abrogates that and that's again complex one dependent right so there's pretty good data to suggest that all cause mortality is somewhat linked to those spikes I mean there's some studies out there But a carbos does the same thing. Yes, it does. >> And a carbos did extend life in the ITP. >> Richard Miller's >> but metformin did not. Both were delivered in the cow. >> So why do you think a carbos which clearly does that and metformin which might do that didn't work? >> Yeah, I I don't have a good explanation to it. Not that that was being measured, right? They didn't have glucose monitors. But I would argue that now that we can clearly see this glucose spike happening that lots of people observe and metformin can abregate it. I wonder if that's a good tool for people to use. I don't know what you think of that. I'm just thinking aloud. Right. You have a glucose monitor or you do it for three months. You get a good good increase decrease. You get you know some idea on metformin. So, so look there are two glucose regul there are three glucose regulating drugs that went into the ITP right there's kagaflozosin a carbos and metformin >> and the way the ITP is designed the drug is always in the food >> so the the vehicle of delivery is always the same kagafalosin and a carbos worked >> worked >> they were there you know not many drugs work in the ITP but those two did and metformin did not and so what do you think explains that difference. >> Yeah. So, um I don't have a good explanation for that. The Cana drug some people argue is a complex one inhibitor too by the way >> in addition to being an SGLT2. >> Yeah. Yeah. There's some papers on it and I think it would be good for us to run in those through our NDI1. I don't have a good explanation for the mice. All I'm just saying is that in humans that glucose spike can be reduced by metformin. I think you would agree with that, right? People should do that study carefully. They're small studies. is anyone can do it who's on a glucose meter who's taking metformin that and anecdotally when I ask people they go oh yeah yeah when I take metformin before a meal that's the key >> how long before >> 30 minutes you know 30 minutes before a meal probably um within 30 minutes it's in the gut you know so so and and the data on the pre-diabetes people metform is much better than the full-blown diabetes it always has been if you're on full diabetes we know the G's GLP1, the triple G. Yeah. And the the SGL2. So, so you and I would both agree it has some beneficial effect and keeping your glucose. >> I completely agree with that. I'm going to go through the four horsemen. >> Yeah. And and I think that that metformin should always be considered a first-line drug in people who are pre-diabetic or very insulin resistant. But the real question is, should a person who's insulin sensitive considerate taking it for these geroprotective purposes? >> Right. Right. So, so I'm going to just argue that you get a better microbiome and you get a better glucose lowering if you're on metformin. >> I I will accept the second. I will plead ignorance on the first because I don't know what a better microbiome is. >> But but but there are these microbiome communities that say this is But these are the same people who tell you that the microbiome is 10 to one your normal cells and blah blah blah and like all of that stuff has been proven to be wrong. >> I know I'm not that is not the reason to do it. I'm just saying because it's in the gut. I always get people saying the whole thing is in the gut now is it going to make my gut leaky and the microbi right? What I'm saying is whatever that is not affecting that in a negative way. >> I'm going to assign very low confidence to that point because I think that is still very very foggy. But the second point is true. It lowers blood glucose. >> Yeah. But but you have to understand, Peter, if I'm going to talk about the gut these days, the large public is dying to know it. Will it make give me a bad microbiome? Whatever that is. >> But I just want to I want I want I want to make sure we're not we're not feeding into Yeah. I just I don't want to feed into the to the to the scientific illiteracy that has become the way we talk about the gut is, you know, good versus bad. Like I, you know, good cholesterol versus bad cholesterol. People still say that it is meaningless concept. >> There are there are microbes that generate butyrate which has been shown mechanistically to be good and those those microbes are increased when you take metformin. So put it that way. But but the second thing is cancer which is where you started. >> So let's talk about so it's failed. >> We can both agree on that on clinical trials reanalyzing. There's always some signal here and there. So the prostate one and there was a subset of patients that it it uh it it it looked pretty good but generally let's just say it's a negative. So why is it a negative? So we did an experiment mechanistically where we took a cell that were very sensitive to metformin and uh and we put it in a mouse. The tumor grew. We gave the mouse metformin. The tumor shrank and that tumor we put that yeast NDI1 back in so it would be refractory. And guess what? the tumors came back. So again, mitochondrial complex one inhibition and by metformin and explains the the anti-cancer effects. I think that part is more widely accepted. Now we and >> what was the what was the uh cell of origin of that cancer? >> That was we did it in two. We did in a lung cancer and we did a a colon cancer. But but here's the thing. >> And how and the metformin was delivered orally in both cases. >> Orally both cases. How do you think how do you think it made its way into the lung cancer? >> Yeah, I'm going to tell you in a second. So, what we had noticed was not only we many people had noticed that if I took 60 cell lines, 10 cell lines, one or two would respond in culture, the other 10 wouldn't care. I could go to a 100 millmer, they wouldn't care barely. So, u a um a student in the lab, Karthik Vasan, he did a simple screen. He took a very sensitive cell line to metformin in culture, the same one in vivo that in a mouse reduced and he added metformin to it and it killed that cell loss. Okay, he added at a dose, it killed it. He basically using crisper, right? So, uh the crisper technology to knock out every metabolic gene. So, he's got 3,000 different clones now with all the metabolic genes knocked out. 2,000 of them like a thousand of them are are are so fundamental for life >> they died incompatible >> incompatible the other I don't know I don't remember what the numbers were let's say there was a thousand that lived and then he asked if I give those metformin who lives >> one guy lived one one one >> guy could live >> it it lost the organic cation transporter >> so it couldn't bring metformin in >> the plasma membrane transporter if you lose it laughs at metformin it doesn't care. Okay. Why is that important? Wouldn't it be nice to do a clinical trial based on whether you're positive for that transporter or not? >> Do we know in the when we screen human cells? Can't we screen for that cation? At least in the I mean that should be knowable. >> Do we not know there's there's three of these transport transporters? Yeah. Yeah. >> Do all three of them transport metformin equally? >> Um uh seems like at least in the cancer one is organic cation transporter three. Okay. But but your point is can you not come up with a diagnostic test? >> So I'll play it one step forward, right? Which is it's very important to know how frequently that's mutated because if that's mutated a lot, it could explain why you have failures in clinical trials. If it's mutated very little, that would that would suggest that that's not the reason. In other words, it's not the delivery of metformin. It's not the failure to deliver metformin sufficiently to the tumor that causes the failure. >> Right? But what I'm going to argue is tumor cells cell else may not even have it to begin with. >> Well, hang on. You're saying they lose them? >> No, no, no. So, the experiment that we did, we made genetic knockouts in an unbiased way and we said, let's lose in each cell individually. >> But the cells were what to start? >> They they were positive. They were positive, but lots of them are not positive to begin with. >> Let me back up for a second. Are you telling me right now, you know, my liver has these cells? Let's just assume I don't have any mutations. You know my gut has them. >> Kidney has them. >> My kidney has them. You don't know if my pancreas has them. >> Your pancre most of the sister cells don't have high robust organic cation transporters or else it wouldn't and high levels of it. And what I'm saying is when you look at the cancer profile. >> Yeah. But you said it only gets in the blood at 10 microar. >> Right. So, so even going so if so you have this huge drop off when you go from from from gut to liver to blood. So if the blood only has 10 to 20 micro sure peak it goes a little higher. >> Okay. But still is that even enough to get it into cells should they have the transporter. >> Yeah. So when we've measured it uh in the tumors as you can find it and more importantly the best experiment we can do is when we give NDI1 and the we aggregate the effect so there was sufficient amount of >> so you see a big enough delta with the two different complex ones >> it's also >> even at that low a delivery >> well 10 microar gets enriched 100x in the mitochondria if it gets delivered because of the the potential so it's cationic metformin is positive If if and you're pumping a negative, right? So when you electron transport's working, it's pumping negative and you bring it in. So people have estimated anywhere from 100 to 500x it's metformin accumulation in the matrix where it binds to complex one. But the but again we can argue about uh did it work? >> So So you're saying we don't even know if a breast cell has this this transporter on it. No, what I'm saying is we didn't go back and try to figure out that were the breast cancers that were given and and we didn't stratify him by organic >> cat. Totally get it. But I'm saying in the in the wild type if if for a woman who's listening to this podcast right now, >> yeah, it probably doesn't have enough. >> It's it's likely that her actual mamry tissue does not contain the transporter. >> Probably doesn't. So then it seems very unlikely that when she develops cancer that it's somehow going to randomly mutate in developing the transporter >> right or or well not mutated but but maybe the anka genes because remember these transporters are not designed to bring in metformin they do have other functions right to bring in other organic cations ions potentially I don't know which what what active transporter what's that >> it's active yeah to ATP exchange >> I don't actually know that okay I actually don't know that. But uh um >> how positive is metformin? >> Serotonin and h you know what I I don't remember this Peter um >> I want to say oh there's something important that it transports okay I heard it's at a low level uh and I can't forgive me but but the simple point being is that we didn't go back and stratify based on the transporter. So >> yeah, >> eGFR inhibitors are given to someone has a mutation eGFR. Her septin is given going back to the mammorary t uh breast cancer to HR2 positive. So we didn't do that right. Another way you could do it is is let's take a tumor that is uh not FDG positive for glucose. It doesn't take up a lot of glucose. There's many tumors that don't as you know. Now we give the patient metformin. If that tumor starts to light up with glucose, you bet Metformin got in and inhibit mitochondrial complex one. You could stratify it based on that, right? Is your tumor metformin responsive by FDG PED low versus high? >> And is it your hypothesis that if metformin is going to have efficacy in an oncologic setting, it's going to do so through mechanism number two? going back to the original four things we talked about where mechanism number two is by inhibiting complex one it's not so much that it's inhibiting the ability of the tumor to generate ATP but more importantly it's the ability of the tumor to generate building blocks for cellular growth it's the anabolic target >> absolutely absolutely because that electron transport makes the TCA cycle go oh and you inhibit electron transport TCA cycle which makes them metabolize for growth are are are lowered and now you can't grow as well. But all of this depends on metformin being efficiently coming in through the transporters and probably through the mitochondria. We've been trying to find out how it gets into the mitochondria. We haven't figured that out. But >> really? >> Yeah, we haven't figured it out. >> We don't know how mitochondria gets from the cytoplasm into the actual inner matrix. >> I don't know how metformin gets into the mitochondria. I know how I know how it gets from the cell membrane. It needs those organic cation transporters. One, two, or three. Yeah. But how it gets we actually the screen was designed to try to figure that out. We didn't. But but you know we stumbled upon something simpler that >> and this [laughter] is just a very super naive question but is there do we are we at the point technologically where we can do um kind of timelapse electron microscopy and and and actually watch uh something like metformin travel throughout this >> I don't think so but someone did uh this fancy cryo technology which I'm not familiar with the the best of the structural and now they can see where metformin binds to complex one >> that's assuming it's already inside. >> It's already inside. Yeah. Yeah. This is different, but it's pretty cool. They figured out in this boot 45 subunit exactly the binding sites of of metformin. Very cool. And they also made a point that it didn't uh inhibit any of the other complexes because some people argue complex 4 might be a site. I don't buy any of that and nobody does in the field other than a few people, but I'm open to it. But complex one clearly is inhibited by mitochondria. uh this NDI1 is a good way to test it >> to test the necessity of complex one inhibition. So, you know, going back to should should you and I take metformin, okay, can lower my glucose, that's not a bad thing. And the cancer effects, well, you could argue that, you know, for us prostate cancer, that if our prostate cancers for whatever reason, god forbid, early lesions, if we were to get them as we age, they happen to be organic cation and transporter positive big if, then maybe there's some efficacy there. But but does that hap you know is that is that reason >> even and even if you deliver it intravenously to put a higher concentration in circulation there's no I mean it's either binary either you have the cation transporter or you don't even if you drove the blood concentration up two log a log you wouldn't >> no no right exactly because because we gave quite a high metformin to kill in that screen and when the when that cancer cell lost the organic cation transporter it became totally refractory treat them at. >> So then is it your suspicion that if if you took a woman with breast cancer um or a man with lung cancer and you could screen their tumor and indeed by some good fortune they had the act the OC >> that metformin [clears throat] would be a potentially potent uh anti-tumor drug. >> Potent is a is a famous last words. Yeah, exactly. How it >> it could be because one of the things it'll do is is >> how much will it prevent proliferation? >> Yeah, it it will not decrease proliferation but the best thing it'll do is they'll stop consuming oxygen and the local oxygen concentrations will start to increase in a tumor which would make it better for radiotherapy and imunotherapy. One of the challenges in amunotherapy there's many but one of the key ones is the hypoxic tumor micro environment is very amunosuppressive. So anytime you can increase oxygen levels that could be helpful for radiation as well as that along with not making the building blocks right but you know we don't screen for any of this stuff and and because metformin is so cheap who's going to go and do these studies go back and do all of this but I guess from a geoprotective if maybe you take it just just in case. So this is more bullish than where you were eight years ago or se seven years ago I said are you going to take metformin and you said no I need to see more data. >> Yeah. Yeah. So at least I know now why it wouldn't work in cancer and why it may work in cancer. I have a good explanation for it and I got a good explanation for the for the glucose lowering. So I'm going to give you the third one. This is the one every day I wrestle with Peter. Should I do it? Should I? Inflammation. >> Right. Right. So I take a statin now even though I don't need to I take a very lowd dose statin and at 50 I decided go to my doctor who's a great doctor and um you know also with Indian genetics there can be but I had pretty good numbers but I and listening to you of course um so I have something for that right I exercise I have something for my muscle be social etc all the sleep etc right but for inflammation and I've been thinking a lot more about inflammation so the city of Chicago which had terrible pollution for a long time really cleaned up its act the last 20 years except this past summer thanks to the Canadian wildfires it's raging but but at one day I think we were the worst in the world and I I I and trust me the last 20 years we've had you can look at the data we we're not a we're not a terribly polluted city at least where I live we've done trees on top of trees on you know on homes etc we've done a lot to make ourselves not and now we have this so what is is what are you going to fight against pollution, right? Pollution induced inflammation. So my friend Scott Buddinger and and Gokan Mutloo um at Northwestern years ago they were giving Beijing level pollution to mice and one cytoine goes up robustly in humans and in mice is 6 and 6 makes you proth thrombotic therefore you're susceptible to cardiovascular injuries you know an MI for example right okay uh and they started taking alvear macrofasages and giving did lowd dose pollution in vitro and they noticed that the pollutants this this particulate matter these small particles were going in the mitochondria and increasing that H2O2 signal and they could show that H2O2 signal was responsible for the IL6 production. So is pollution, particulate matter pollution, mitochondria increasing H2O2, not to kill as a signal for inflammation. >> And by the way, does the pollution have to be PM2.5? It h it has to be that one. That's what they did. Yeah. Uh yep. And the crazy thing is I was like, "Oh, Scott, you got to put metformin." And he goes, "What do you mean?" Like Metformin inhibits complex one and it'll prevent the H2O2 from being released. He's like okay. So they did it in vitro and invivo it's a public paper in cell metabolism and beautifully they could show in vivo giving it in the drinking water that it lowered the six >> and is that because the liver is making I mean >> the alvear macrofasages it's the alvear macrofasages >> to the alvear macrofasages they took it up because we could see in the alvear macrofasages is >> how are they getting the metformin? >> They're they're taking it up >> out of the blood. >> Out of the blood. So they have >> they have the transporters but but they they're good at at I think at also taking up stuff of what we want to do is put NDI1 back in those macrofasages to definitively show it did take it up and it inhibit complex one because it could have been an effect from somewhere else still right it maybe the gut everything but but the key point is we're still working on the mechanism um Peter and we've done by the way we've given flu with metformin and there was always a COVID signal with metformin decreasing uh the inflammation. So uh in mouse models of SARS KV2 or influenza when people give drinking water metformin it lowers the pathology. But my simple point was I'm going to be exposed to pollution. Again there's no human data with metformin and pollution. measuring CRP or something like that for a couple of months and seeing if it was lower at a population level. >> What do you think IL6 would be more sensitive than CRP? >> I think CRP's uh would be equally sensitive, I think. But again, it's it's people just haven't designed the trials correctly to think about this. So, here's a last one about inflammation. Do you know what clonal hematopoesis is? >> Yes. >> Right. So this is as we age >> but tell people because it's an important part of heart disease that doesn't we probably don't spend enough time talking about >> so so as we age H um uh our hematopoitic uh stem cells which make all our blood cells including our tea cells and our B cells and our red blood cells and our platelets as we age those uh uh can pick up a particular mutation and and actually mutation in the enzymes that run epigenetics largely and they become rogue clones and they overtake and they somehow contribute to cardiovascular disease definitely inflammation and the level of clonal hematopesis can range from 3 to 20% and of these rogue clones taking over as we age so UK bioank did this study they looked at clonal hematopois and they somehow and I'm not an epidemiologist controlled for diabetes and everything people on metformin had lower incidence of clonal hematopois 450,000 UK bio The same people made a mouse model of of clonal hematopoesis and they gave of uh metformin it decreased clonal hematopois >> how much >> very significantly it was it was quite remarkable here's the best part some smart reviewer said you should put ndi1 and show me is complex one and it was so in other words metformin binding to complex one prevented those clones from outgrowing from the mechanism you pointed out because the building blocks weren't there. >> But again, how are we getting so lucky that these cells have OCTs? >> I I was to be honest with you, the dosing they did was was 50 microar in vitro. Oh to have some of these effects. I was shocked. >> And they were doing this in human cells. >> They did it in mouse cells. Yeah. Three papers came out at the same time to the same conclusion. So speaking of reproducibility three different ways is two of them were in nature the other one was in nature communications all three of them said if you inhibit electron transport chain you can prevent clonal metapoesis and the best drug that is safe if is metformin so so Peter let's let's just wrap up the metformin there's a couple of lessons in in the metformin and on the mechanism side right um and we're going to get into your some of your other uh favorite supplements perhaps Perhaps we should first think about when you take an oral supplement or an oral drug, where does it go? Does it accumulate everywhere or does it only go certain places? The second thing we have to know is what is its target? I've argued is complex one and because I've made a complex one that is refractory to metformin binding but works like complex one. So someone should always show me the target and make that target work perfectly fine but not bind to metformin or whatever other drug or supplement. And the third one is maybe you don't even care about where it goes and what it binds to. Does it work in humans, not in mice only, right? And so the data suggest and and you you tell me if you agree with this as in a normal person it'll it'll keep your glucose levels down. If you take it before a meal, not a bad thing. If you get lucky, if it has that transporter, then it will um perhaps lure the clones from the cancer clones from from arising. And if you're lucky to have that, the third one is clonal hematopoesis that happens with age. lowers according to these studies and in our study with pollution and and in some studies that people have done with te- cells it seems to be a a low uh sort of low inflam anti-inflammatory agent. So it's so is that enough for people to take it? So so what are the risks? The risk is B12 deficiency but you can fix that. The other one is citrine. You can easily take a supplement for that. Uh people get nausea so people sometimes people don't take it but many people don't. So that's where we're at. >> Do you think it crossreacts or interferes with other glycemic agents such as GLP1 agonists or >> I've asked Yeah. What do you think? I I've asked people that. They say no. >> I don't I don't think I have an informed enough opinion. >> I just don't. Yeah, I don't either. Um Um There are people who do both as you know. Um so I I I I just don't. So it's the inflammation part, right? because I'm not going to take an NSAD, right? I'm not going to take a leave every day. I take it sometimes and that's pretty potent. >> But then the question becomes like why did aspirin fail in the ITP, right? >> Why why would COX inhibition which should be reducing inflammation had no impact on >> reduces different kinds of inflammation perhaps, right? >> It right this is much more. So we can show metformin inhibits 1 beta, IL6. So what would we need to do in humans? Right? I've lost track. Is tame happening? What's what's going >> I don't know. I don't know. But but again and uh the the cancer trials, the tame trials, every trial in metformin um because it's cheap, it's been guided um you know smartly by whatever data is in humans and could we redo these trials based on mechanism. Mechanism being the insights we have now. put glucose monitors is to see you know over a year how well did the metformin that people took just to know whether it did anything maybe it doesn't maybe some people for whatever reason it doesn't get absorbed maybe their transporters are low all right so have some indication and maybe measure CRP or some other uh measure clonal hematopois if there's ways to do that right there's there is all of this sort of stuff as far as the cancer that's almost impossible you're just taking it you know that something that may help protect against uh or if you get an early lesion, it might slow it down. And but I like the inflammation and the lowering glucose as the two actionable ones. And is is there anything else that really can do? >> Well, I think if you're lowering uh chip, that's that's pretty interesting. >> Yeah. Yeah. We'll have to see how well that that uh that manages, right? >> And that hasn't been demonstrated in human uh cells yet. Well, it has uh and it has been also demonstrated in the UK bio bank as just a correlation. >> Yes, but it hasn't been proactively tested in humans. >> Well, it's does uh No, no, no. You mean as a clinical trial? No. No. Someone needs to do that and and then but it'll take 5 years, right? >> But that would be a very interesting trial in a high-risisk population. you take a high-risisk cardiovascular disease population that is otherwise well-managed because one of the questions I find interesting in in ASVD is how much like I I'm interested in the topic of residual risk right so why is it that some people can have uh significant risk then you manage them well with blood pressure >> uh and lipid control but then they still progress disease progression occurs at different rates right >> and there so in other words there's some residual risk beyond on the apo and beyond the hypertension and let's assume they're not smoking and how much of that is chip related >> and if you can find that population and you you you you do an RCT there with and without metformin >> and you track >> the you know hematopois the clonal hematopois question I think that could be very interesting >> yeah yeah I just think from the by the way speaking of heart disease or heart failure you know speaking of metabolism one of the best new drugs are these SGL2 inhibitors Right? They're the SGL2 is basically in the kidney. So you pee out, you know, they call it sweet pee, right? The urine, you just pee out the glucose uh into the urine and that somehow is communicating to the heart and telling it, you know, a failed heart that you're you're good to go. Now, uh the idea that heart failure is due to mitochondrial dysfunction is the one I really have my doubts in humans. I just don't think the evidence really points to that. Again, you [clears throat] can make a mouse model where the heart fails because the mitochondria are failing, >> right? But that doesn't mean that's >> that's what's happening. And people the results are mixed in humans. But the best evidence to me is that you give put somebody on an SGL2 inhibitor, it somehow globally reprograms their metabolism. And that's a very loosey goosey non-mechanistic term. You know, maybe increases a little ketones or fatty acids, but their heart works fine now, which means there could not have been intrinsic mitochondrial defects. Yeah, >> because if they were SGL2 inhibitors wouldn't work so well. >> Now, I want to talk about a whole bunch of supplements that get talked about a lot. Before I do, though, um I just want to go back to something you said at the outset. I asked you, "Hey, how would you measure mitochondrial function?" And you said, "I'd put a needle in somebody and pull out tissue and and but but that's important because there are lots of people out there that are hawking tests that are claiming they have tests. They have blood tests, they have breath tests, they have all sorts of tests to measure mitochondrial function." As one of the world's experts on this topic, are you aware of any blood test, breath test, any sort of test that a person can do to measure their mitochondrial function? If they see this, what should they be thinking? >> I have not looked at all these tests. I don't follow these tests. I don't care to simply because in a perfect world, I can't think of how I would design it for all the reasons we just talked about. That's the real problem. I mean, look, if I had one, then maybe, you know, this struggling scientist professionally and personally would uh would come up with one, Peter, but you know, I got nothing other than a cheap drug called Metformin and a glucose monitor, you know. So, it's it's difficult for me to imagine how that test looks like and whether it reproducibly measures something that has of value >> because I'm assuming what these tests are trying to measure are >> content. Well, yeah. I assume I again I'm not I'm also not an expert in this whatsoever. I assume they're measuring metabolic intermediates and they're somehow trying to impute based on your orginine arnathine citrine levels, alpha ketoglutarate levels. Oh, based on that, based on the ratios and levels of all these things, we can tell you how your mitochondrial function is cararnnitine. >> Yeah. Why is that kind of bogus in your mind? >> Well, because a it's in steady state. It doesn't really tell you flux, which is how fast the system is running or not running. You could see an increase in something. Is that because you're running so fast and you still have a lot or is it something backed up? That's problem one. >> Yep. >> Right. >> That's the whole cap inhibitor problem back when we were dealing with that drug. >> Yeah. So, it's just um Yeah. Again, when I myself haven't done a deep dive on something, I generally try not to be overly critical, but I'm just making a phil I'm making a conceptual point that, you know, if you and I sat together for an afternoon and said, "Here now, tell me all the things I could measure and how would I measure it?" Could I come up with a test? No. >> All right, let's talk about some of the most popular supplements that people promote as >> Can I Can I just finish just with cancer real quick? We didn't touch cancer because this is another misnomer people. So the original hypothesis of cancer the number one hypothesis of cancer not number one but the oldest from the 1920s was by gentleman the warber effect that many people have heard. So Otto Warberg got a Nobel prize for the discovery of cytochrome oxidase which is the main oxygen consuming enzyme of the electron transport chain. Yours truly did his PhD on cytochrome oxidase kinetics. So for me, Otto Warberg has a place for the discovery of that enzyme electron transport chain. So So Otto Warberg in the 1920s noticed that cancer tissues make a lot of lactate on a tabletop compared to normal tissues. There's plenty of oxygen and so if you have oxygen, you shouldn't be making lactate. So he actually made an intelligent guess which is that mitochondria of those tissue of the cancer is dysfunctional. their electron transport. He called it injury to respiration. His famous line is a prerequisite for developing cancer. Today we know that many cancers that make a lot of lactate don't do it because electron transport or injury to respiration. In fact 95 98% of cancers have a very intact electron transport chain TCA cycle. And the reason is because they use it to make ATP but also to make those anabolic precursor the metabolites for growth. There are a few outliers that have a TCA cycle mutation or an electron transport chain mutation. Okay, those tumors that arise is they basically take the uh macroolelecules for growth, the metabolism growth from the uh from the blood. They're good scavengers. >> Yeah, this is this is an important point to tease out. So the Warberg effect is an effect. Most cancers adhere to it. It's the causality that's incorrect. It's not that the Warberg effect is the result of deficient electron transport. It's that the Warberg effect is there as a result of a cell that needs to reproduce and grow and grow and grow and create building blocks. And really, the first time I read this was in that very famous 2009 science paper with Matthew and and Lou and Craig. Um, so, so very important distinction, but unfortunately this is sort of where the the internet and and people who maybe don't fully understand this will turn it into cancer is a mitochondrial disease and it's all about your mitochondria and if you just take mitochondrial supplements, you'll never get cancer. Like that's somehow or if you have cancer, just take mitochondrial supplements, you're going to be fine. >> Yeah. Yeah. This is complete and utter nonsense. Okay. >> So, uh, let's turn to some famous mitochondrial supplements, right? Uh, urthan, >> right? >> Okay. What can you tell us about urylthan? >> We're going to use the metformin principles all over again. Oral. >> Yep. >> First pass, gut. >> Uh, the gut cells do take it up. The second pass, very quickly, liver. I actually didn't know this until recently because I went back and read a very nice paper. Uh, I think one of your guests previously might have been on I think it was on the paper on inflammation and urithin. If you look at the supplementary data, uh how much is in the plasma of urolithin of those people who took it? Picoggrams undetectable because the liver puts gluconic acid on it. So uralithan and conjugated which then is in the plasma. So you can barely detect uraliththan in the plasma. It's conjugate uraliththan plus this sugar midy. is higher like five to 10 microar that moy cannot get into a cellin can. >> So what breaks the conjugate? >> So there are enzymes that can break that conjugate. Uh they're usually found around immune cells sometimes on in muscle repair tumors. But this is a bit of a conundrum I don't quite understand. Right? And I'm sure you appreciate where I'm going with this is like well hang on how does this work? this this thing rapidly becomes so either it's having effects on the gut directly which it might and we know how important the gut is is the other thing is that when it's made a conjugate it has to be deconjugated and that's happening in my reading of the enzymes that do this tend to be more related to immune cells okay so that's that's part one and the second thing is like with metformin what's its target so with metformin people debate Is it complex one? Is it not complex one? Is it complex 4? Is it something else? The way we went about showing it's complex one is we found a refractory version of metformin that wouldn't bind and to show was complex one. Right. So with uralithin they say it's mphagy that it promotes you know bad mitochondria. It gets rid of them. Okay. >> But wait I I've missed three steps. How is it even getting into a cell? >> Well I don't know that. So the only way could get into a cell is that locally like immune cells for example uh again I don't know the literature that well on it. >> Do we know if there's a urthan transporter that can get unbound or unconjugated urthan? >> I don't think the conjugated one can get in in I think the unconjugated for sure gets >> I mean clearly somebody could label ur and give it to somebody and then look at where it's taken up. Has that been has that experiment been done? >> I've never seen it. So that's what the metformin experiment was, right? Someone took a C11, they said, "Oh my god, it's in the gut." Someone did an FDG PET. Oh my god, it's in the gut. People like me say, "Okay, let's focus on the gut." Right? So again, I'm just using the principles of metformin which can be used the principles of urolithin. Where does it go? What I do know is that they measured it in the plasma. It seems like a lot of it is converted in the liver to this uh uriththan plus a sugar muy. That's that's was my simple point. >> So that >> and if that's the case >> then it has to get deconjugated y >> somewhere in the body maybe in immune cells because immune cells can supposedly release the enzyme that that deconjugates it and then the uriththin gets into that that localized population. So if you could um assume it gets into a cell, how likely is it that can it can induce mphagy or what's the evidence that it is doing that? >> People have seen it induce mphagy or or mitochondrial biogenesis, but where is the target? It's been 10 years. Where's the target? I don't think anybody's ever told me a target or published a target. And it's interesting because metformin is free. There's no money to be made in it, but yet the the research has been done. Why is it not the case in uralin that that's that that's being done? In other words, um is the is the argument that urthan is a supplement and that it's over- thecounter and therefore it's not worth studying. Whereas metformin is a regulated drug and that's why it's worth studing. I mean, like I'm trying to understand why there is such a glaring gap in knowledge for over-the-c counter supplements. >> I would argue there isn't. Uh it's just as how efficacious they are. Um right. So, Peter, forgive me. I have to go back to a supplement that's widely used. Bourberine. >> Oh, yes. >> Oh, you're going to like this. So, bourberine people take, right? Hey, so news flash, bourberine doesn't look like metformin. In our studies, when we give mice bourberine, it lowers the glucose levels. Okay? If we have NDI1, that yeast refractory in the gut, glucose levels go up. So, bourberine, as far as I can tell, works exactly like metformin. And gee whiz, metformin is probably cheaper than bourberine and is regulated. So, use metformin if you're going to use bourberine. Sorry. >> Same concentrations you're seeing in bourberine as metformin. >> We are using the concentrations of bourberine that were effective in lowering in mice. Right. We just have to. So we use the concentration of metformin that's widely used to lower glucose levels. We use bourberine to lower glucose levels. The lowest dose. >> It is always interesting that people do prefer a supplement over a drug. It's like I'd rather have something that's unregulated and I cannot verify the quality versus a drug. >> Right. But but my point is as far as we can tell and it's in our pre-print paper, people can see it, it it acts like metformin even though structurally it's different. And so my point is it's probably like metformin and it's >> but you don't have the granular detail for bourberine in terms of you don't actually know where it's binding complex one. You just know it is working on complex one based on the experiment. >> Right? So let's go back to uralithin. Why? So so so you could you could ask now why don't you work on uralithin? >> You're a mitochondria guy. Here's another new fascinating drug. Well, okay. So, we could start to figure out there's ways that you can figure out how a drug or a metabolite binds to a protein. There are new techniques. They're called like proteium thermal shift assays is um so there's ways to do this. Um I'm waiting for the aha data [laughter] right in humans and or even in mice and the data. So, the human trial in in in muscle, I mean again the trials are small. They're not they're not g- whiz the the one that I have liked recently there was a mouse trial with anti-tumor immunity that that was pretty pretty good they gave it uh to see if uriththan would make u te- cells more effective against a tumor the other one is they >> and what did that experiment show >> oh it it helped yeah >> why do you think it did >> um they argued through mphagy and they did a nice experiment they knocked out u the thing that controls mphagy uh and then it didn't work as well. So, so it's a pretty good u as good of a biological study. Um, so that got me thinking a little bit about urithythin. The other one is they gave it to people and they looked at CD8T cell whether they were exhausted in and uh I think it was in the elderly and you know you have some amount of exhaustion and and you had a little bit less with uralithn and and again this is a paper where they show that the plasma is mainly UDP sorry it's a uralithin bound to uh sugar moy but again you know there's an effect there a decreased inflammation >> relative if we're going to use metformin as our baseline Where do you put the promise of urylan relatumor data was good? I think with a lot of these supplements there may be a window. For example, maybe uriththan could improve anti-tumor immunity and you should use it with cartis cells. People get cartis cells for a couple of months. Maybe you could do a uralithn trial in that. Why not? Based on that one study, right? But but but compared to metformin, I don't see how you know it doesn't it's not remarkably lowering glucose effects or or having you know um other effects that we just discussed with metformin. Not enough to make me say let's use that. No. >> Okay. What about alpha ketoglutarate? >> I like that one a lot and I study it myself. Uh actually I study a different version um uh something in the family of alpha keto. The reason I like it is because alpha ketoglutarate we do have targets probably too many 75. So it's if alpha ketoglutarate is there, it's going to run your demethylase enzymes working well. It'll cut potentially keep DNA methylation levels down, you know, your so-called voodoo epigen. >> Sorry, is it doing that? Is it is it um is it keeping methylation down or is it reducing methyl groups? Like is it competing for >> No, no, no. So, so, so the methyl groups put it on the DNA. The enzymes that [clears throat] get rid of it, it keeps those enzymes from working well. Okay, >> right here's the only issue. How much do you need for alpha ketogluterate in a cell to run those enzymes maximally? you know 100 microar right you have a lot of alpha ketoglut around it's >> so is it is it ever rate limited >> is it ever rate limiting I don't know that as we age it does go down but does it go down enough >> so what's the experiment what's been done >> well people are now giving alpha ketoglutarate there's a famous study I think Brian Kennedy's group did that with the females uh uh had a better uh outcome than males did the mice did and they're doing human trials in I mean and hopefully they'll do them enough that we'll get parameters but I could imagine like alpha ketoglutarate again working for inflammation under certain conditions or one of my favorite studies uh and I wrote a a perspective on it it's not my study came out of other groups uh where they gave alpha ketoglutarate genetically they manipulated or as supplement and it helped against colitis and happened against 5FU the chemotherapeutic drug so in other words it maintained gut health it promoted stem cells to become more secrettory compared to absorptive which help maintain in gut health. Could you imagine giving alpha ketoglutarate in those settings? Right. So instead of thinking of a geroprotective, right? These are to me they're going to be niche and I think people who are doing them maybe should think about them. You know, it's like uh you love this study. I know I the rapamy vaccination one. Yeah, I love that study. >> But to do this, you you really need to go down an IND pathway >> as opposed to a supplement pathway. You you have to turn you have to turn this into a drug. Yeah, >> right. You you have to have an indication. >> You have to be able to make a claim. You have to be able to test a meaningful and serious hypothesis. >> Yeah. >> Um Okay. Citrine. >> Uh well, we just said that it it uh can >> potentially with metformin. >> Potentially with metformin. Yeah. >> Okay. Carnitine. [laughter] [gasps] >> Well, carnitine helps get fatty acids into the mitochondria. That's what carnitine does. The question is, >> is it meaningful? Is it rate limiting? >> Is it rate limiting? I go back to the rate limiting. Do you you and I I assume you're still a meat eater? Uh I am. Um you know, and even people who don't eat meat, they probably get sufficient amount of carnitine and to have your fatty acids working. And so, >> all right, the big one, CoQ10. Um I think statins it makes sense sometimes uh because it can hit the CoQ pathway upstream. So you can imagine certain and statins maybe that get in the muscle high enough are lowering CoQ levels. Does it get to the point where CoQ again becomes rate limiting? And so anecdotally I mean you know this better than I do Peter. People say that the COQ helps them and I can >> I feel like the trials have not been successful that yeah uh again there's a bioavailability problem. Um um but for what else would you use it for? For normal health? >> No, you have enough code. >> Okay. Now we've already talked a little bit about NAD. So anything you want to say about the NAD precursors NR and NN >> to the listeners? There was a nice article written in the New York Times recently about NAD. Does it work? And they got a lot of experts. I like that article a lot. The experts were very good about at uh you know making their disclosures. They have a company they don't have a company. So that was important. Uh if you read the article even those experts say you know does NAD again decline and normal aging to levels that become rate limiting? And the answer seems largely no. again could the NAD precursors be used in a special setting so there's a >> certain disease >> certain disease so or or >> so there's a nice paper that came that liver regeneration can be boosted yesterday by giving NAD supplements >> from a reputable group >> sorry what can be boosted >> liver regeneration >> oh liver regeneration >> yeah so you could and I can and the mechanisms and what they talked about kind of made sense to me and it's a nicely done study from a very reputable person at University of Pennsylvania Joe Bower so I I like that study so I Totally imagine >> but liver regeneration after liver surgery or after transplant surgery I mean it's pretty pretty extreme case >> pretty extreme right it same with could it work for anti-tumor immunity could it work under special conditions etc etc absolutely I'm open to that but but not for gerrotective I just don't see how and it's based on mitochondrial dysfunction causes the mitochondria not to regenerate NAD because that's what mitochondria do let's give NAD supplements >> yeah which again we should point out was unsuccessful in the ITP. Um, okay. SS31. Now, this is actually pharmaceutical grade. This is treating what's it called? Bart syndrome. Bart syndrome. >> So, this is because there is a a mutation in a gene and that makes cardioipin. Cardiolipin is found in mitochondria. Again, it is necessary for cytochrome C oxidase that Otto Warberg did his research on, now did his uh PhD on. and uh cardiolipin levels dictate the efficiency of that enzyme to work. It uses the oxygen makes ATP etc. Um these people have low amounts and the FDA approved this SS31 as a way to stabilize the little cardipin there to boost the efficiency of that enzyme. Some people argue that this SS351 SS31 interacts with a lot of proteins and overall like is like a glue to the electron transport chain. Here's another one by the way. I would say we don't know the mechanism at all. >> The drug is delivered intramuscularly. How is it delivered? >> I don't know. I don't know how it's delivered and uh but but we don't know there is not an exact target of that drug >> or even a good putitive hypothesis other than it's cardiolippin. Okay. >> Yeah. So that it's a drug that's shown a very very weak effect in a very very extreme and rare genetic disease but it is being touted as a mitochondrial boosting drug that should be taken by everybody. What is the case for that? >> Uh again are mitochondria being is your mitochondrial rate limiting right now? No. Well, or or is is cardiolippin rate limiting? >> Cardiolipin rate limiting. Fine. Yeah, because the trial was done in in cardio uh lipid depleted conditions and I would argue no. So, so I don't again the drug could be repurposed in certain mitochondrial mutation patients which might have some problems and I'm sure they're going to test it now in those settings and I hope it works because there there is a deficiency but for you and I and for most people I just don't see that. And how about methylene blue >> which again has a very clear clinical indication. Uh but beyond beyond the clinical indication where do you see is it something we should be just generally taking for mitochondrial health? >> Well um I'm glad you asked methylene blue. We're going to go back to my old friend cytochrome oxidase again. Isn't it amazing how all these supplements somehow interact with the things we've been thinking about for for years. So what it does is is complex one has NADH. It goes to three and four. One and three can generate a super oxide in H2O2. What it four cannot it takes electrons from complex one methylene blue from NADH and it passes it on to complex four which gives it to oxygen. You bypass one and two >> sorry that's two >> goes goes from one. So usually you go from one oh I thought it was two. So one and two both go into three of the electron transfer chain. three goes to four. I'm saying it takes electrons from one and gives it to four. That's what methylene blue does. Now one and three cannot generate as many electrons for H2O2. So you can imagine diseases where H2O2 signaling is a problem. Maybe methylene blue is a way to to uh to decrease those electrons from generating. But again, you know, is that that's a hypothesis that I have uh that that's how if it could work, it would work. But how much does it get in? And as you know, it can inhibit monomine oxidasis which detoxify dopamine and serotonin and people on serotonin um uh receptor uptakes, right? It if you take too much of methylene blue, you could get serotonin toxicity. the levels that people take are much lower but but you know the biology hasn't been really worked out of method and the trials are >> yeah and also I think the the therapeutic window of that drug is pretty narrow >> very narrow for that reason >> yeah okay outside of >> but it is interesting how it works with cytochrome oxidase and the shuttle there hasn't been enough research done on that but the clinical trials haven't looked >> great I don't think even for dimension Not at all. Not at all. Okay. Yeah. >> Um, what about hyperbaric oxygen? I get asked about this all the time. It's amazing how many times a week I get asked by somebody if they should buy a hyperbaric oxygen chamber. >> No, please don't. So, people are both into high oxygen and low oxygen therapy. And uh, this one is for sure bad >> outside of wound healing. >> Outside of wound healing. Yes. Yes. So, we've I've worked a lot on both of them. In fact, I got my whole career started on working on low oxygen and and then we moved to high oxygen. What I can tell you in high oxygen now to be fair, people do this for a short amount of time, 60 minutes. If you take people in the ICU and you keep them on high oxygen, they want they I I work in an ICU department. I'm not a physician, but I talk to them. They are dying to get those people off high oxygen. And and because the longer you keep somebody on high oxygen and we've done mice experiments on high oxygen, it causes scinessence of your lung epithelial cells, it causes cell death. It's there is there's been absolutely no benefit to the lung being exposed to that level of oxygen. Now, is 60 minutes going to cause all sorts of probably not. But if you're doing it all the time, and I don't think it's going to cause cell death, but it might cause cell scinessence. And that's my one worry about it. I just I've worked with high oxygen mainly in cell culture, mainly in animals. It's nothing good. >> You realize why all of this attention exists, right? Like what you might like why why are people so obsessed with hyperbaric oxygen. I think it comes back to that very um uh I'm going to try hard not to editorialize my thoughts. It it comes back to that Israeli study from a few years ago that looked at tieamir length. >> Oh, yeah. Yeah. in this. And so so unfortunately if if you were to incorrectly believe that tieumir length has anything to do with longevity, you would look at that study and say, "But look, these people, they sat in hyperbaric oxygen chambers, their tieumirs got longer. Clearly that has an anti-aging benefit." So um >> many holes there. I >> I mean the these are holes. >> Yeah, exactly. These these are the kind of holes you can drive 18wheel trucks through. Uh so aside from that study, is there any is there anything else that is generating this belief? >> Well, I think the other one is more oxygen better for the mitochondria >> maybe. >> Okay. Well, let's talk about the other end of that spectrum. >> Low oxygen. >> Low oxygen therapy seems pretty good for athletes. >> Yeah. So, so what's nice about low oxygen is that low oxygen and so un so high oxygen there's no receptors for high oxygen. Okay. High oxygen largely if it's very high, we've shown this causes oxidative stress at damaging levels. So we can engineer a mouse and overexpress one of these antioxidant proteins and the mouse dies and now the mouse lives longer. We've actually the aptosis cell death pathway. If we disengage that people the mice can survive hyperox. So hyperoxy and we can show it causes scinessence cell death. So, so we have a pathways is but there's not a direct way hyperoxy is causing that. I think it's just causing so much oxygen that you just make a lot of free radicals or destabilizing the respiratory chain. The low oxygen has a very nice system which is called the Hif prolyus VHL. Greg Smensa, Peter Ratcliffe, Bill Kalin got the 2019 Nobel Prize on this. And so when we're hypoxic, this pathway gets activated. One of the consequences is EPO ariththropoid which increases your hermatic. The other thing is uh the low oxygen increases your your ventilation right uh the pulmonary system vasoc constricts those are independent of hif years ago we showed likely the sensor for those is mitochondrial there's probably many other things hypoxia does >> outside of an athlete who wants to increase red blood cell production is there any reason for a normal person >> no >> to to to use >> well remember so an athletes okay and the people on high altitude have mechanisms but you know a lot of people especially the elderly get pulmonary edema when they go to altitude. Yeah, >> right. This is well known. In fact, we've studied hypoxy induced pulmonary edema. So this idea that hypoxia is a panacea. Now again, could hypoxia be used in certain control settings, certain ways is but >> like should it be combined with chemotherapy for example? Can it make a tumor cell more susceptible to chemo or radiation? >> Well, people argue that about hyperoxia as well, right? More oxygen and more free radicals. So again, maybe in those sort of things, but just to take it for kicks because you're going to live longer. I don't I don't think so. >> All right, let's bring it back to cytochrome again. Red light therapy. >> Apparently, it hits cytochrome oxidase, my my enzyme. And how, you know, it's weird. So people say that we always have a little bit of nitric oxide around in our bodies and eno can bind to cytochrome oxidase and red light therapy would pop it off and make it more efficient. I actually don't know how red light um therapy is having its effects in vivo. By the way, the way we showed metformin and complex one inhibition with NDI1, there is an ancient enzyme not from yeast but from CCORT. If you inhibit complex one, you can override it with this alternative oxidase. So I have a way to test that. If again, will I test red light theory? Well, unless it's having these those clinical trials that show something amazing, we have a good way to test that theory. >> So, so we I mean the one thing where clinical trials have definitely shown efficacy for red light is in skin rejuvenation. >> Yeah. >> Right. So, do you I mean and I I I feel like I used to know how this worked. Uh is that working through collagen synthesis? >> Yeah. But but again um years ago we showed that a little bit of H2O2 in skin cells in epithelial cells promoted their differentiation and people argue that red light therapy could increase a little bit of H2O2 and I wonder if it's the mechanism we found years ago. So so I wouldn't mind studying it. There's another interesting benefit that that you see in some of the trials in red light therapy, which is on a if you get a significant enough portion of your body covered in red light, you see glucose uptake enhanced. >> Um, it's it's it's actually pretty interesting. So, there was one study that looked at oral glucose tolerance tests and the AU, the area under the curve of glucose went down when a person had x amount of time of their back being hit with red light. Now, I remember when I read this, I was like, "Wow, that's that's a lot." It was actually a pretty significant reduction in AU. Um, but then I did sort of back of the envelope math to see how it compared to exercising. And of course, it wasn't as much glucose reduction as you would get from an equal amount of time of modest exercise, but it was a lot relative to just laying there given the fact that you compare it to the placebo. So, again, I don't recall sort of thinking through the mechanism. I don't wait but doesn't that smell like maybe in the back of the skin >> maybe it inhibited cytochrome oxidase which would then force glucose uptake kind of like the gut metformin maybe simple as that >> and it's I remember wondering and maybe they did I don't know if they measured lactate but you would expect to see lactate go up if it was forcing more glycolysis right >> yeah yeah so but but minute you make a lactate in your blood your heart loves to take up lactate every lots tissues love to take up. So >> you'd have to make enough to be to overwhelm the other cell, >> but maybe maybe so there's something there where again we can engineer mice where we can make a a cytochrome oxidase homalologue that is not red light responsive and test formally where the red light therapy goes through modulating cytochromoxides. I mean I think this is my big lesson with all of these you know find the target factory the target where does it go and then let's look at the human data and how it's efficaces and you know and all in all when I when we just went through these things things to me metformin I'm not saying people go run out and use it it's still better than all of these it's approved lots of people use it maybe lowd dose anti-inflammatory maybe cancer very weak definitely lower glucose >> citrulin and B12 >> yeah I have a feeling I'm going to be getting a lot questions about this from patients who are going to be wondering and I mean insulin sensitive patients we have we have lots of patients that do take metformin but but >> um and I have to be honest with you Nav I'm really on the fence I just don't know man >> I me too a lot my family members ask it um you know >> the inflammation part people like the best I think I but again it hasn't been it's been the least studied >> yeah and maybe maybe that's an interesting case is I take those patients that have persistently elevated CRPS that we otherwise can't come up with any reason for and maybe we do a metformin trial in those patients and see if we can can knock down some inflammation >> and measure their clonal hematopes. >> I was just about to say that the chip is is also a super interesting thing that I was unaware of. So >> right >> um anyway now this has been absolutely fascinating uh I >> can I make one other point just just and this is a bit self- serving on I have no conflict of interest as I said >> as we have gone through all these journey about what mitochondria do and especially all the supplements and all the big drugs they all end up doing something GLP1 we didn't talk about SGL2 metformin all the supplements they have something to do with metabolism something to do with mitochondria 30 years ago we put money 40 years ago we started to put money in the human genome project which I think has been a complete spectacular success we know the genome all the sequencing technologies that came out we've really gotten the granularity of human genetics more and more UK bioank all of this has come of age right [snorts] we have never had a moonshot for metabolism whether it's the government whether it's a foundation whether it's philanthropy to be clear place like Michael J. Fox Foundation for Parkinson's and you know and I have a grant from them and we think Parkinson's is a complex one disease and we're trying gene therapy with this NDI1 and to and they've given us some money. So I'm very thankful to them and we get some money from the government over the years to do all our work but it's not at scale nothing like the human genome project right so my thing is I know academia there's some issues as but right now we should be doubling our efforts it's in science especially in metabolism which has been underfunded for 40 years I mean you make a great >> why do you think that is Nev >> well because >> is it simply that it got dwarfed by the genomic revolution >> by the genomic revolution and and and you remember when you were a student they said now we know our genome we're going to know everything about the human disease 30 years from now this will not exist gene therapy well it works great for monogenic diseases and some other diseases but everything else is idiopathic unknown ideology all the >> polygenic y >> yeah but and also the toxins that we're exposed to more and more like the Parkinson's one they all had mitochondria you know so but there hasn't been a large scale and and and people like me were early adopters to metabolism after the golden generation of metabolism people have passed away, the Krebs of the world. And so in my world, there hasn't been that many. Now, in the next generation, there's a lot more, but I'm afraid they will probably walk away because there won't be enough money for metabolism because it's dwarfed by the genomic revolution. So, I I really would like people to make a push for the moonshot of metabolism. >> But, but now, do you think it needs to be philanthropy or government? Do you not think this could be biotech driven? it could all I would the best case scenario would be all three that's what the genomics people did right there's biotech and genomics for sequencing machines that people buy right there's biotech for for the drugs but the the the basic science comes from um uh the government and then you have the philanthropy filling in all the holes I'm just saying yes there is parts of faith but it isn't to scale right and I know people are you know have are down on academia I would argue we should double triple our money for biomedical research. So the last 10 years that you talk about which I completely agree is what we want to save and if we don't have a healthy population last 10 years we're going to bankrupt the nation because of health care cost you know it and I know it as people live at the same time and I'm on record of saying this and probably you'll get some flak for this you have the right Peter you do and the taxpayers and say you know what are you being as efficient or are you being as innovative as you should be for the 21st century in academics's current model and I I don't think we are. I think it's time that academia change how its business model runs and but at the same time give us three times as much money in return and okay so I'm not saying just give us money and we'll keep on doing what we did. We need to change we need a new model a new system. I'm very open about it. I will encourage I know you do notes um I hope you put this there was a uh the grand people in science 10 years ago people who ran Princeton NIH director Nobel prize there's four of them who wrote something called rescuing the biomemed research enterprise rescuing they wrote like a white paper in in the proceedings of the national academy of sciences because they're national academy members and they outlined what they thought were the problems and solutions I am not saying we all have to agree on their solutions or even the problems but it's pretty good start and that was 12 years ago. >> And what came of it? >> Nothing. Zero. We did the opposite in my opinion. >> What were some of the things that they pointed out? >> No, some of the things about >> like risk takingaking >> risk takingaking uh maybe um different style labs having um uh uh how uh the costs uh that the that the universities impinge on the government. So in other words, getting um having more skin in the game. So it's just not a revolving business model. They had a lot of good ideas in there and you know I'm not the right person who's thought about all of this stuff. What I will say the biggest challenge is that uh like a lot of things in the US it's become kind of an imperial power at the top as opposed to decentralized labs and decentralized uh uh divisions of biochemistry or or medicine you know where there's like you know if you're Google you have 10 separate divisions that answers to the top but they're all kind of independent and decentralized. We're way too centralized now at every level. >> And you're saying that not just at the NIH level, but at the university level. >> Absolutely. At the at the biomedical research level way way way too centralized is the uh you know there's cancer centers. There's there's you know the everything goes through the dean's office or the president's office is you want decentralized you know this better than I do. Decentralized >> they don't run like startups. >> Yeah. >> Yeah. So sorry for that. No, I think it's a really important I think that's a super super interesting we have to keep on uh and somebody should think about a metab you know if someone wants to support a moonshot of metabolism give me a call [laughter] >> not just for me but for the field I'm talking about. Okay. All righty. >> Thanks man. >> Great. Thank you. [music]